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Beware of determining and declaring  
your opinion suddenly on 
any subject; for imagination  
often gets the start of jugdement... 
 
When you employ the microscope 
shake of all prejudice, nor  
harbor any favorite opinions... 
 
Remember that truth alone is the  
matter you are in search after; 
and if you have been mistaken;  
let not vanity seduce you to persist in your mistake. 
 
H. Baker, London, 1742 
The Microscope Made Easy 
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General introduction and aim of the thesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This introduction will be partly published under the title: 
Oesophageal pathology following ablation of Barrett’s mucosa   
Curr Diagn Pathol 2005 (in press)
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Barrett´s oesophagus  (BO) is the major precursor of oesophageal adenocarcinoma and is 
endoscopically characterised by a salmon-pink, velvety-like appearance of the distal 
oesophageal lining (Fig.1). Histopathologically, BO is defined by the presence of a 
specialised columnar epithelium with the presence of goblet cells, which is referred to as 
intestinal metaplasia (1,2). Initially three types of BO were discerned, i.e. gastric-fundic type 
epithelium with parietal and chief cells, junctional type epithelium with cardiac mucous 
glands, and specialized columnar epithelium with intestinal type goblet cells. Presently, cancer 
risk in BO is considered to be restricted to patients with intestinal metaplasia. The transformed 
mucosa may have a foveolar, sometimes villous pattern with irregular spaced pits, crypts and 
glands. Often non-specific inflammation is found, occasionally ulcerating. The metaplastic 
epithelium mainly consists of two cell types, i.e. columnar cells and goblet cells. Furthermore, 
few neuroendocrine cells and Paneth cells might be discerned. Intestinal metaplasia of the distal 
oesophagus is thought to be the result of long standing gastro-oesophageal reflux (3,4).  
 
 
Figure 1. 
A] Normal squamous lining of the oesophagus- endoscopic view 
B] Barrett´s oesophagus with a red velvety, salmon-pink appearance-endoscopic view 
A B 
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Histopathologically, the development of an oesophageal adenocarcinoma appears to be 
preceeded by epithelial dysplasia. Dysplasia is defined as a neoplastic proliferation within 
epithelial glands without affecting the basement membrane. Dysplastic changes can often be 
found surrounding an adenocarcinoma in BO. In addition, longitudinal follow-up studies have 
documented the gradually increasing severity of dysplasia eventually resulting in 
adenocarcinoma. These observations suggest that dysplastic changes might be taken as early 
indicators of incipient malignancy. This is important because on the one hand patients with BO 
have a 30-40 fold increased risk for oesophageal adenocarcinoma, but on the other hand only a 
low percentage of BO patients eventually develop cancer (1,2). 
 
 
Figure 2. 
Histology of the successive stages of epithelial atypia in Barrett´s oesophagus (BO). A] specialised intestinal metaplasia. There are no 
dysplastic features, i.e. no atypia and many mature goblet cells. B] BO with low grade dysplastic features, i.e. mild atypia with elongated 
nuclei, but normal cellular orientation, and presence of dystrophic (immature) goblet cells. C] BO with high grade dysplasia, i.e. severe 
atypia with nuclear stratification, loss of cellular orientation, and an evident lack of goblet cell differentiation. D] early Barrett’s 
adenocarcinoma dysplaying an invasive cribriform growth pattern. 
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The incidence of adenocarcinoma is rising rapidly in the Western world (5). The development 
of adenocarcinoma follows a multi-step sequence from intestinal metaplasia to low grade 
dysplasia (LGD), high grade dysplasia (HGD) and, finally, adenocarcinoma (1,6,7; Fig. 2; 
Table 1).  
 
Table 1. The Vienna classification.  
Cat. 1: negative for dysplasia 
Cat. 2: “indefinite” for dysplasia 
Cat. 3: low grade dysplasia (LGD) 
Cat. 4: high grade dysplasia (HGD) 
Cat. 5: invasive neoplasia 
 
Most patients known with BO are offered endoscopic surveillance with biopsies to detect 
dysplastic changes at an early stage (8). These endoscopic surveillance programs are costly 
and also have impact on patients’ well-being. The (cost) effectiveness of these programs is for 
several reasons under discussion: 1] the grading of dysplasia is subject to intra-and 
interobserver variation (9,10), 2]  endoscopy is not able to differentiate between non-
dysplastic and  dysplastic Barrett’s mucosa, and 3] there is no clear evidence whether early 
detection of dysplasia prolongs the survival of patients with BO (11,12).  
Low grade dysplasia is rather indolent and not a reliable hallmark for malignancy (13,14). 
Moreover, dysplastic BO is often multifocal within the Barrett’s segment (15). There is no 
doubt that high grade dysplasia is an indication for surgery or endoscopic mucosectomy, since 
it confers a high risk of developing into adenocarcinoma, but some controversy concerns the 
extent of HGD and the risk of adenocarcinoma (16). Buttar et al. (17) investigated whether a 
limited extent of HGD had the same potential for cancer development as diffuse HGD. They 
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found that patients with focal HGD are less likely to develop adenocarcinoma than those with 
diffuse HGD. Weston et al. (18) followed 15 patients with focal HGD. Approximately 50% of 
these patients progressed, either to multifocal HGD or cancer (18). Only limited information is 
available on the prognosis of patients with early adenocarcinoma of the oesophagus (T1 stage). 
Five-year survival rates of 100% for T1 tumours limited to the mucosa have been reported, 
with rates declining to 60% for T1 tumours invading the submucosa (19-22).  
Endoscopic mucosal resection (EMR) of HGD and early cancer in Barrett’s oesophagus is 
associated with low morbidity and mortality rates and offers an alternative to surgical 
resections. Ell et al. (23) reported, however, recurrent or metachronous carcinomas in 14% of 
patients after EMR for HGD or early adenocarcinoma. In the last decades several groups have 
applied photoablative techniques to remove Barrett’s epithelium. The aim of these techniques 
is to destroy the pre-neoplastic mucosa and to restore the normal squamous lining in an anacid 
environment. By doing so, a decrease of the premalignant potential is expected. Ablating all 
of the Barrett’s mucosa may completely abolish the risk of neoplastic progression. 
 
 
 
Figure 3. 
The principals of ablation by photodynamic therapy (A) and argon plasma coagulation (B).  
 
 
 
 
  B
 A B
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ABLATION METHODS 
The most commonly used techniques are thermal destruction by argon plasma coagulation 
(APC) and photochemical destruction by photodynamic therapy (PDT) (Fig. 3A&B). Other 
techniques are multipolar electrocoagulation (MPEC) and destruction of the Barrett’s mucosa 
by liquid nitrogen or ultrasonic energy (24).  PDT and APC are most widely used and seem 
equally effective and safe. Photochemical ablation using PDT is based on the intracellular 
accumulation of a photosensitizer in tissue. There are different photosensitizers available. The 
most commonly used are an enriched form of hematoporphyrin (Photophrin) and 5-
aminolevolinic acid (ALA). ALA is a precursor molecule in the heme biosynthetic pathway, 
which induces the endogenous production of protoporphyrin IX (PpIX). Photophrin is 
administered intravenously to patients, whereas ALA is can be taken orally. PpIX is activated 
by photoirradiation using laser light with an appropriate wavelength. This generates singlet 
oxygen production resulting in tissue destruction. APC employs a cautery probe that transfers 
electrical energy through an ionized, electroconductive plasma of argon gas to the tissue 
surface, again resulting in tissue destruction.  
The choice of therapy is largely dependent on the depth of tissue penetration. Barrett’s 
mucosa is approximately 0.5 mm thick and dysplastic mucosa slightly thicker (25). Using 
APC, injury is controlled by a tissue depth of 1-2 mm because of insulating properties of the 
scar formed after coagulation. The depth of tissue penetration is difficult to regulate and 
depends much on the operator’s experience. A deeper tissue penetration can be obtained by 
increasing the power setting.  In case of ALA-PDT, endogenous accumulation of PpIX is 
predominantly within the epithelium, therefore tissue damage is limited to the mucosa. In 
combination with hematoporphyrin as photosensitizer, the penetration is 2-5 mm and involves 
the submucosa as well (26, 27). Thus, in theory, both thermal and non-thermal ablation 
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techniques could result in tissue penetration, which is deep enough to completely ablate 
Barrett’s musoca with or without dysplasia.  
 
ABLATION RESULTS 
The majority of studies using ablation using APC and PDT have focused on dysplasia and 
early cancer with a complete removal rate in up to 80% of patients (28, 29). For patients with 
metaplasia without dysplasia, APC has been the most commonly used technique (30-35). 
After 1-6 sessions of APC, a success rate of BO eradication ranging from 42% to 98% can be 
achieved. In the first clinical trials, however, buried glands were found underneath 
(neo)squamous epithelium with frequencies varying between 8% and 30% (30, 32, 33). In 
other trials (34, 35), the incidence of buried glands was lower, probably due to the use of 
higher PPI doses and a higher power setting of APC. Using a low energy rate, Basu et al. (36) 
reported buried glands in 44% of patients. They further found that the length of BO before 
treatment was a predictive factor for persistence, and there was a trend that persistent gastro-
oesophageal reflux was also involved.  
Two groups performed a randomised trial comparing APC and PDT in patients with 
metaplasia or LGD only. In the study by Hage et al. (37) subsquamous islands were more 
commonly found after APC (50%) than after PDT (4%).  Kelty and al. (38) also found 
subsquamous glandular structures after APC and PDT in comparable frequencies (21% vs. 
24%). One group performed a randomised trial comparing APC and MPEC in 52 patients 
with metaplasia or LGD (39). Endoscopic ablation was achieved in approximately 85% of 
patients in both treatment groups, whereas complete histological ablation was found in 
approximately 75% for both methods. Subsquamous specialised intestinal epithelium was 
identified in 69% of the patients, but serial sections revealed that in fact in all cases the 
specialised epithelium extended to the surface (39). It therefore seems irrelevant to describe 
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the presence or absence of microscopic foci of BO as underneath squamous epithelium. It can 
be concluded from these studies that the replacement of normal squamous epithelium is only 
rarely 100% complete. In addition, endoscopic ablation therapy is associated with long-term 
complications, such as stricture formation, particularly after Photofrin-PDT. The risk of 
progression to cancer is low in patients with remaining columnar metaplasia without 
dysplasia. However, in two cases development of adenocarcinoma underneath regenerated 
squamous epithelium has been reported (40,41). The precise nature of these malignancies is 
not clear, however likely they originate from remaining BO after ablation therapy.  Up to 
now, the follow-up of most ablation studies has been too short to make a meaningful 
statement. 
 
HISTOPATHOLOGICAL ASPECTS OF ABLATION 
There are three hypotheses for the origin of Barrett’s metaplasia: (1) de novo: stem cells of 
inflamed squamous epithelium in the exposed area differentiate to Barrett’s epithelium, (2) 
from the transitional zone at the squamo-columnar junction, transitional cells differentiate to 
either squamous or columnar epithelium in response to injury, similar to the cervix uteri and 
the anal canal, and (3) the so called “duct cell metaplasia” theory meaning that stem cells 
located in the glandular portion of the duct colonize the oesophagus when damage to the 
squamous epithelium has occurred (42). Likewise, three mechanisms of squamous re-
epithelisation have been suggested by Biddlestone et al. (43) who studied squamous re-
epithelialisation after laser or photodynamic therapy and acid suppression: (1) encroachment 
of adjacent squamous epithelium, (2) extension of epithelium from a submucosal gland duct, 
of which the upper part is lined by squamous epithelium, forming squamous islands and (3) 
squamous metaplasia in the Barrett’s epithelium itself (43). The latter suggests the existence 
of pluripotent stem cells within the Barrett’s mucosa itself capable of differentiation along a 
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squamous lineage in an appropriate environmental condition (44, 45). However, as stated 
previously, squamous regeneration may be incomplete and Barrett’s epithelium may persist 
within the regenerated squamous epithelium or as foci underneath the restored squamous 
lining and hence be invisible for the endoscopist. Barrett’s epithelium may also recur after a 
period of time, especially when acid suppression is not adequate (46, 47).  
It is important to obtain adequate biopsy specimens (i.e. surface epithelium and lamina 
propria) in order to examine the treatment effect. Examples of BO before and after ablative 
treatment are depicted in Figure 4. Recommended are 4-quadrant biopsies per 1-2 cm 
throughout the (treated) Barrett´s segment and from any irregularity observed at endoscopy. 
Endoscopic ablation therapy results in loss of landmarks, i.e. the Z-line is no longer visible. 
However, adequate sampling from the junction of the gastric cardia and distal oesophagus 
should be performed. Since squamous extension into the gastric cardia has been reported (48), 
the clinician should carefully report at which location the biopsy specimens were taken in 
order not to confuse intestinal metaplasia at the site of the gastric cardia from true Barrett’s 
metaplasia.  
At present, a diagnosis of BO is defined by the endoscopic presence and the histopathologic 
finding of intestinal metaplasia, i.e. the presence of goblet cells, regardless of the extend of the 
lesion. After ablation, recurrent or residual Barrett’s epithelium may manifest itself as a single 
or a few glands, which impairs histopathological grading. In these cases, it might be difficult, 
if not impossible, to grade metaplastic glands buried under neo-squamous mucosa. This is not 
only due to the small number of Barrett’s glands, in which epithelial atypia cannot be 
adequately judged, but to the scarcity of surface epithelium, which can help in grading (Fig. 
5). In these cases it might be helpful to perform Ki67 and P53 stains (Fig. 6). The aspect of 
regenerating squamous epithelium can be complex and should not be confused with neoplastic 
changes (Fig. 7). However, nuclear atypia is always absent in the squamous nests, which can 
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be situated deeply in the mucosa. It also seems feasible that the restoring squamous 
epithelium extends into Barrett’s glands, or alternatively, in the ducts of oesophageal mucous 
glands (Fig. 7). This should not be mistaken for adeno-squamous or mucoepidermoid 
carcinoma. It is not useful to judge biopsy specimens obtained within a few weeks after 
ablation, since damage caused by the therapy is not yet repaired. Normally, repair is complete 
within one month after ablation.  
Introduction  
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Figure 4. 
BO before (A, C, E) and after (B, D, F) ablative therapy. A,B] Barrett’s metaplasia without dysplasia. This patient was initially treated with 
PDT, but because of remaining BO additional APC was administered 4 months later. This was followed by an interval of histologic 
remission. However, 2 years after the start of therapy BO recurred (panel B), which was still present at the last follow-up endoscopy. C,D] 
LGD patient treated with PDT only. Panel D shows remaining or recurrent BO 3 years after the start of therapy. In the last follow-up biopsy, 
Barrett’s metaplasia without dysplasia was present. E,F] Patient with a long history of BO with HGD, who showed persistence of HGD 
(panel F) after treatment with PDT. Therefore, several courses of additional APC were given. After a 1½ year interval of histologic 
remission, again HGD was found, 3 years after the start of therapy, which was followed by oesophagectomy. The resection specimen 
revealed several foci of HGD but no signs of lymphatic dissemination. 
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Figure 5. 
BO after ablation. So-called “buried” glands can be seen under regenerating squamous epithelium. A] overview, and B] detail showing a 
metaplastic gland within the squamous epithelium (arrow) that is likely to make contact with the surface mucosa.  
 
 
 
 
Figure 6. 
A small focus of BO glands under squamous mucosa. A] H&E, atypia is difficult to assess. B] Ki67 immunostaining revealing many cell 
nuclei in proliferation phase. This would be a normal finding in the neck region of the glands, but this aspect cannot be adequately 
determined. C] p53 immunohistochemistry showing a negative pattern, which could favour a diagnosis ‘negative for dysplasia’. 
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Figure 7. 
Neo-squamous epithelium displaying clear characteristics of regeneration, which need not to be confused with neoplastic proliferation. A] 
overview and B] detail illustrating a “pseudo-invasive” histology without nuclear atypia. C] overview and B] detail showing regeneration 
within Barrett’s glands or ducts of oesophageal mucous glands. Also in this case no cellular or nuclear atypia is present. 
 
GENETIC ASPECTS 
Barrett’s oesophagus and oesophageal adenocarcinoma are characterised by genetic 
instability, which is reflected by both cellular and chromosomal abnormalities. Oesophageal 
carcinomas contain many alterations, often situated in regions known to harbour tumour 
suppressor genes and oncogenes. Genetic alterations can already be found in the preneoplastic 
state, i.e., in Barrett’s metaplasia, but also in intermediate stages, such as LGD and HGD. In 
the following, the most relevant (cyto)genetic changes commonly seen in BO and BO-related 
cancer, i.e. ploidy and proliferation abnormalities and the most critical genes in the 
preneoplastic phase, i.e. p53, p16 and APC will be discussed. 
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Aneuploidy is a modification in the cellular DNA content, resulting from uncontrolled cellular 
division. Cell cycle abnormalities such as increased S-phase and G2/tetraploid cell fraction 
and the development of aneuploid cell populations are often seen during progression to cancer 
and can be detected by flow cytometry. Studies have found aneuploid cell populations in 
patients with Barrett’s oesophagus. The proportion of these cells are increased in the 
successive stages of Barrett’s metaplasia, dysplasia and finally adenocarcinoma, in parallel 
with an increased proliferative activity (49-51). Cell cycle abnormalities can already be found 
in patients with BO without dysplasia (52). Aneuploidy has been found to indicate an 
increased risk of neoplastic progression (53). 
Proliferation aberrations are commonly investigated by means of either flow cytometry or 
immunohistochemistry using antibodies against Ki-67. Ki-67 recognizes a nuclear antigen 
that is present in proliferating cells (those in G1, S, G2, and in M), but is absent in resting 
(G0) cells (54,55). The mucosa can be divided into the luminal surface, the upper crypt, the 
lower crypt and the underlying glandular zone. Normal gastric mucosa typically shows 
nuclear Ki-67 reactivity confined to the glandular zone and base of the crypts. In BO without 
dysplasia, additional positive nuclei appear in the lower crypts, but the upper crypts and 
surface are without nuclear Ki-67 reactivity. In LGD, nuclear Ki-67 is seen in the upper crypts 
with occasional surface reactivity, and in high-grade dysplasia such cells are abundant on the 
luminal surface. Invasive carcinoma cells are most often diffusely reactive when stained with 
Ki-67 antibody. The most widely applied parameter of nuclear Ki-67 immunostaining is the 
labelling index, i.e. the proportion of positively labelled cells to the total number of cells 
within the proliferative compartment (56-58).  
The p53 tumour suppressor gene, located on chromosome 17p13, encodes a 393-amino-acid 
protein, which is important in the regulation of the cell cycle. The gene plays an important 
role in the G1 phase (59). When DNA damage has occurred, for instance due to chronic 
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mucosal inflammation in gastro-oesophageal reflux disease, a functioning p53 gene will arrest 
the cell cycle in late G1, so that DNA damage can be repaired, prior to the start of the S-phase 
of the cell cycle. When damage cannot be repaired, the cell will go into apoptosis. However, 
in certain situations the gene can mutate, functionally converting the p53 tumour suppressor 
gene into a dominant oncogene. Several studies have examined the role of the p53 tumour 
suppressor gene in BO along the metaplasia-dysplasia-carcinoma sequence.  
Previous studies found a low frequency of p53 protein overexpression in patients with non-
dysplastic Barrett’s epithelium and higher frequencies in patients with dysplasia or 
adenocarcinoma. This led to the suggestion that p53 mutation is a late-phase phenomenon in 
tumour development. In more recent reports it was shown that p53 overexpression in mild 
dysplasia cases was associated with progression to more severe dysplasia, whereas absence of 
p53 overexpression was associated with a more favourable prognosis (60-67). Thus, p53 
overexpression appears to be a marker of the malignant potential in BO. 
The p16 cyclin-dependent kinase (CDKN2/MTS1/INK4) gene is a tumour suppressor gene, 
which is located on chromosome 9p21. The p16/CDKN2 product inhibits the phosphorylation 
of the retinoblastoma gene (Rb) by forming a binary complex with the cyclin-dependent 
kinases Cdk4 and Cdk6 (68). By preventing the phosphorylation of Rb, p16 can inhibit cells 
to entry into the cell cycle. Thus, loss of function of the p16 gene may lead to unregulated 
cellular proliferation. Alterations of the p16 gene may occur by allelic loss, gene mutation, 
and methylation-induced silencing of the p16 gene promoter. Promoter hypermethylation and 
allelic deletion appear to be more frequent events than mutation as mechanisms for the loss of 
function of the p16 gene. Investigations using consecutive biopsies from patients with 
Barrett’s oesophagus, have demonstrated the relationship between alterations of p16 and the 
clonal evolution of cell lineages in Barrett’s metaplasia (69-71). These studies indicated that 
9p21 loss of heterozygosity, CDKN2/p16 hypermethylation and p16 gene mutations occur in 
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diploid cell populations and precede the development of aneuploidy and cancer. Furthermore, 
p16 gene alterations were detected prior to loss of heterozygosity observed at 5q (APC gene), 
18q (DCC/SMAD4 gene) and 13q (Rb gene). By examining the clonal ordering of these 
genetic alterations, these studies have suggested that there may be no obligate order of 17p 
(p53 gene) and 9p (p16 gene) loss of heterozygosity or mutation, and that both abnormalities 
precede the development of cancer. LOH of 9p seems more common than 17p loss and can be 
detected over a greater region of the diploid Barrett’s epithelium.  
The APC (adnomatous polyposis coli) gene can be found on chromosome 5q21. The APC 
protein is located in the cytoplasm, where it interacts with several other intracellular proteins, 
including B-catenin, a protein that can enter the nucleus and activates transcription of growth-
promoting genes. An important function is to degrade B-catenin. Inactivation of the APC gene 
therefore leads to an increase in the cellular level of B-catenin resulting in increased cell 
proliferation (72). In BO, allelic loss of APC is frequently found in adenocarcinoma, but there 
are variable results concerning the presence of APC LOH in premalignant lesions. Gonzales et 
al. (73) failed to detect LOH of APC in Barrett’s metaplasia or dysplasia. Generally, APC 
mutation or loss appears to develop at a later stage in the progression pathway to 
adenocarcinoma. In addition, allelic loss at the APC locus was detected in metaplastic 
populations, which had apparently progressed to dysplasia (74). 
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Aims of the thesis 
 
1. What is the natural history of neoplastic progression to adenocarcinoma in patients with 
BO?  
2. Which patient characteristics are associated with malignant progression? 
3. What is the most effective ablative method, APC or PDT, for the removal of Barrett’s 
epithelium? 
4. What is the effect of ablative techniques on histological and cell biological parameters in 
BO? 
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Introduction to the papers 
 
Chapter 2. A follow-up study was performed of a cohort of patients diagnosed between 1973 
and 1984 with BO who had not undergone standard endoscopic surveillance. The aim was, 
firstly, to obtain data concerning cancer risk, using current guidelines for the diagnosis of BE. 
Secondly, we investigated which patient factors present at index-endoscopy were associated 
with neoplastic progression. 
 
Chapter 3. A randomised trial was conducted with the aim to compare 5-aminolevulinic acid 
induced photodynamic therapy (ALA-PDT) with argon plasma coagulation (APC) for the 
complete removal of BO. Macroscopic reduction of BO was evaluated, and histopathological 
examination was performed to assess the extent of reversal. Furthermore, side effects of both 
ALA-PDT and APC were evaluated. 
 
Chapter 4. The effect of ablative therapy on Barrett’s oesophagus on the cell cycle and 
cytogenetic level was studied. The (pre)malignant potential of persisting or recurring glands 
from patients with BO treated with PDT and/or APC was assessed by p53 
immunohistochemistry, Ki-67-related proliferative capacity, and DNA ploidy status as 
measured by interphase in situ hybridisation.  
 
Chapter 5. A loss of heterozygosity (LOH) analysis was performed using a panel of 9 
polymorphic markers residing at loci of known tumour suppressor genes (P53, P16, DCC, 
SMAD4, APC). LOH patterns of residual or recurrent Barrett’s oesophagus after ablative 
therapy were defined in order to assess its malignant potential. 
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ABSTRACT 
 
Background: Data on cancer risk in patients with long-segment Barrett’s oesophagus (BO) 
from older studies are often difficult to interpret, since the definition of BO has evolved from 
an endoscopical to a histological diagnosis. In this work the diagnoses in the Rotterdam BO 
cohort on current standards was redefined to obtain more accurate data on cancer risk in 
paients who had not undergone standard endoscopic surveillance. In addition, it was 
determined which patient factors present at index endoscopy were associated with neoplastic 
progression in BO.  
Methods: The Rotterdam BO cohort comprises all patients with ≥3 cm BO, diagnosed at 
endoscopy between 1973 and 1984. In the present study, only patients with intestinal 
metaplasia were included (n=105). Follow-up data were obtained by questionnaires and/or 
interviews with patients or treating physicians. A Kaplan-Meier analysis was used to estimate 
20-year risks.  
Results: The mean length of BO was 7.1 cm (range: 3-15 cm). Cancer in BO developed in 
6/105 (6%) patients, and high-grade dysplasia (HGD) in 5/105 (5%) patients during 1329 
patient-years of follow-up, which equals one cancer case per 221 patient-years and one HGD 
case per 266 patient-years. After a mean follow-up of 12.7 years, 72 (69%) patients had died; 
only 4 (6%) of them had died from oesophageal cancer or its treatment. A longer length of 
BO was associated with an increased risk of progression to HGD or cancer (p<0.02). Six of 
24 (25%) patients who ever had low-grade dysplasia progressed to HGD or cancer 2-16 years 
after a diagnosis of BO.  
Conclusion: The annual risk of developing HGD or adenocarcinoma in patients with long-
segment BO is 0.83%. Death due to adenocarcinoma is, however, uncommon, even in a 
cohort of patients with long-segment BO.   
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Barrett’s oesophagus (BO) is an acquired condition with a premalignant potential. Long 
segment BO (with a length of 3 cm or more) is found in 3-5% of patients undergoing 
endoscopy for symptoms of gastro-oesophageal reflux (1,2). Patients with long-segment BO 
have a 30 to 125-fold increased risk of developing oesophageal cancer compared with the 
general population (3,4). Malignancy in BO develops through a multistep sequence from 
intestinal metaplasia to low-grade (LGD) and high-grade dysplasia (HGD) and finally 
adenocarcinoma (5,6). The incidence of oesophageal adenocarcinoma has risen rapidly over 
the past two decades (7-9), and the 5-year survival rate of oesophageal cancer after surgical 
treatment is still below 20% (10). Therefore, in many centres an endoscopic surveillance 
programme has been implemented for patients with BO to detect dysplastic changes in 
Barrett’s epithelium at an early stage. Presently, there is no evidence that this strategy reduces 
mortality from oesophageal cancer (11). Moreover, BO remains unrecognised in most 
individuals (12,13). 
In the 1970s and 1980s, a diagnosis of BO was based on the endoscopical presence of 
columnar-lined oesophagus with a length of at least 3 cm, regardless of the histology. 
Nowadays, the definition of BO requires the histological presence of specialised intestinal 
metaplasia in the oesophagus, irrespective of its length. Only patients with this type of 
epithelium have been shown to be at an increased risk of developing oesophageal cancer (14). 
The change in the definition of BO makes previous reports on the incidence of oesophageal 
cancer difficult to interpret.  
Previously, we reported an incidence of one case of adenocarcinoma in BO per 180 
patient-years follow-up in a cohort of 155 patients, who were endoscopically diagnosed with 
BO between 1973 and 1986 (4). These patients had not been offered endoscopic surveillance, 
although some had undergone repeat endoscopies at random intervals and for various reasons. 
In order to obtain more accurate data on the cancer risk in BO, we defined our cohort of 
patients with long-segment BO again and based it on current guidelines requiring the presence 
of intestinal metaplastic epithelium (14). Since most of these patients had not been offered 
surveillance in those days, we also had the opportunity to study the incidence of 
adenocarcinoma in patients with BO who had not undergone standard endoscopic 
surveillance. Finally, we determined which patient factors present at index endoscopy were 
associated with neoplastic progression in Barrett’s epithelium in order to better define which 
patients with BO were at an increased risk of developing HGD or adenocarcinoma in BO. 
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METHODS 
Study population 
From the database containing all patients referred for upper gastrointestinal (GI) endoscopy to 
our unit between 1973 and 1986, those with endoscopical evidence of BO were identified. 
The following three criteria were applied, as was done in our previous report: (a) Barrett’s 
epithelium of at least 3 cm length, (b) no oesophageal cancer or HGD at entry, (c) follow-up 
of at least 3 months. These patients form the original Rotterdam Barrett’s oesophagus cohort 
(4). In the present study a new criterium was added: (d) the presence of intestinal metaplasia 
in at least one oesophageal biopsy specimen taken at upper GI endoscopy, either obtained at 
index endoscopy or at a repeat endoscopy. 
 
Endoscopy and histology 
Data on the length and the presence of abnormalities, such as erosions, ulcers, nodules and 
strictures, at index endoscopy were obtained from the original endoscopy records. Biopsy 
samples from BO were taken with a standard biopsy forceps. Additional biopsy samples were 
obtained from any endoscopical irregularities such as ulcers, nodules and strictures. To be 
able to fulfil criterium (d) (see above), histological slides from biopsies obtained at index 
endoscopy and/or repeat endoscopy were reviewed. Patients with no histological slides 
available at index endoscopy or during follow-up were excluded from analysis. The 
hematoxylin & eosin stained histological slides were reviewed by one experienced GI 
pathologist (HvD). In case of intestinal metaplasia, grading for dysplasia was performed 
according to the guidelines as described by Haggitt (5) and Montgomery et al (6). However, 
we did not apply the classification ‘indefinite’ for dysplasia. 
 
Follow-up 
Data on follow-up were obtained by means of a questionnaire, sent to the general practitioner 
of each patient. The questionnaire contained the following questions: 1) Is the patient alive or 
had he/she died, 2) Does/did the patient have signs or symptoms of oesophageal cancer or 
has/had the patient developed proven oesophageal cancer, and 3) In the case of death, what 
was the date and what was the most likely cause. If necessary, additional information was 
obtained by phone from general practitioners, medical specialists, nursery homes, patients 
themselves or relatives. When a patient had moved, the population registry was contacted to 
trace the patient’s new address. In case of oesophageal cancer, detailed information on 
histology, treatment and outcome was acquired through the physicians involved. 
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Statistical analysis 
Risk factors for the development of HGD or cancer in BO were compared with the Kaplan-
Meier curves using log-rank tests. Twenty-year cumulative incidence rates for cancer, and the 
combination of cancer and HGD, as the end-point were determined. The Cox regression was 
used for multivariate analysis. A P value <0.05 was considered statistically significant. 
 
RESULTS 
Characteristics of patients 
A total of 105 patients met the inclusion criteria (58 M, 47 F) met the inclusion criteria. The 
mean age at the time of the BO diagnosis was 63.4 years (range: 16-96 years). The mean 
length of the BO was 7.1 cm (range: 3-15 cm). Thirty-eight (36%) patients had an ulcer in BO 
at index endoscopy.  
At entry, 64 (61%) patients had non-dysplastic Barrett’s epithelium, and 11 (10%) patients 
had LGD. In 30 (29%) patients, the degree of dysplasia at baseline could not be established 
because intestinal metaplasia was not seen in the first biopsy samples (n=17), or biopsy 
samples were not obtained during the first 3 months of follow-up (n=13). Biopsies from these 
patients were obtained after a mean period of 3.6 years (range: 0.3-15.6 years) after index 
endoscopy. The diagnosis in the first available biopsy samples from these 30 patients was 
non-dysplastic Barrett’s epithelium in 29 patients and LGD in 1 patient.  
All patients had a complete follow-up. The mean follow-up period was 12.7 years (range: 
0.3-25.5 years), accounting for a total of 1329 patient-years of follow-up. Forty-six (44%) 
patients had undergone 2 ore more (median: 3) repeat endoscopies at a mean interval of 4.4 
years (range: 0.5-15.5 years) between endoscopies, whereas the other 59 patients underwent 
no or only one repeat endoscopy after index endoscopy. At the end of follow-up, 72 (68.6%) 
patients had died at a mean age of 78 years (range: 34-99 years).   
 
Development of HGD and adenocarcinoma in BO 
At the end of follow-up, 6/105 (6%) patients (3 M/3F) had developed adenocarcinoma in BO 
during 1329 patient-years of follow-up, which equals one cancer case per 221 patient-years or 
0.45% per year. The mean age at diagnosis was 78 years (range: 68-88 years). Tumours were 
diagnosed 4.6, 6, 10.5, 10.8, 13.5 and 15.9 years after index endoscopy. Of these patients 5 
were symptomatic at the time of diagnosis, whereas one patients was not.  
At the end of follow-up, in 5/105 (5%) patients (4 M/ 1 F) HGD had been detected, which 
equals one HGD case in 266 patient-years or 0.38% per year. The mean age at diagnosis was 
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62 years (range: 53-77 years). HGD was detected 0.6, 1.8, 5.8, 12, and 18.9 years after index 
endoscopy. Of these patients, 3 underwent endoscopy for symptoms of dyspepsia, whereas 2 
had no symptoms. 
 
Mortality and causes of death 
Five of six patients who developed adenocarcinoma in BO had died at the end of follow-up. 
Their mean age at death was 81 years (70-96). Two of these five patients had undergone 
oesophageal resection: one died from postoperative complications, the other died from a 
myocardial infarction 16 years after the oesophageal resection without signs of recurrent 
cancer. Three patients did not undergo surgery, due to advanced age (n=2) and severe 
comorbidity (n=1). Two of these patients died shortly after the diagnosis of oesophageal 
cancer from metastatic disease, whereas the other patient died 4 months later from end-stage 
COPD. One patient with Barrett’s cancer did not undergo resection due to advanced age and 
is still alive and asymptomatic 5 years later, at the age of 93 years.  
Four of five patients who developed HGD in BO had died at the end of follow-up, at a 
mean age of 70 years (range: 63-77). One of these patients had undergone an oesophageal 
resection and died from acute pancreatitis 2.3 years later. One patient refused surgery and 
died 5.6 years later from a myocardial infarction. One patient died one month after the 
diagnosis of oesophageal cancer from cardiac failure. One patients underwent an oesophageal 
resection and died  4 years after surgery from liver metastases (the cytological diagnosis from 
these metastases was a mucinous adenocarcinoma, which suggests that it was from 
oesophageal origin). One patient also underwent an oesophageal resection and is alive and 
well 6 years after the operation. The resected specimens of the last 2 patients did not reveal 
evidence of adenocarcinoma.  
In summary, 4 deaths (mean age 75 years) out of the 72 patients (6%) who had died at the 
end of follow-up at a mean age of 78 years, were related to neoplastic progression in BO. A 
list of the causes of death of all 72 patients who had died at the end of follow up is presented 
in Table I. None of the seven patients who died from an unknown cause had obvious signs or 
symptoms of oesophageal cancer. 
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Table I. Causes of death in 72 patients with Barrett’s oesophagus who died during follow-up  
  
Cause of death Patients     Cancer in BO    HGD in BO* 
Barrett’s cancer    3  2  1 
Cardiovascular disease   26  1  2 
Pulmonary disease    12  1  
Unrelated gastrointestinal (GI) diseases 11    1 
Other (non-GI) malignancies   5     
Sepsis      2 
Paget’s disease    1 
Postoperative bleeding    2 
Postoperative complications   1  1 
Multiple organ failure   1      
Old age     1 
Unknown#     7 
 
*HGD= high-grade dysplasia; BO= Barrett’s oesophagus; GI= gastrointestinal. 
# No signs of oesophageal cancer. 
 
Risk factors for neoplastic progression to HGD or cancer in BO  
Progression to cancer was detected in 1/11 (9%) patients with LGD at entry, compared with 
3/64 (5%) patients with non-dysplastic BO at entry. HGD or adenocarcinoma in BO was 
detected in 2/11 (18%) patients with LGD at entry, compared with 5/64 (8%) patients with 
non-dysplastic BO at entry (Table II). Twenty-five patients had LGD detected in their index 
or repeat biopsy samples. In 10/25 (40%) patients, repeated biopsies were taken after this 
diagnosis. Of these, 5 patients had no evidence of dysplasia in at least one repeat biopsy, 
whereas the other 5 patients showed persisting LGD for a period of at least 5 years after the 
LGD diagnosis. Six of 25 (24%) patients, who ever had LGD, progressed to HGD or 
adenocarcinoma. The time between diagnosis of LGD and progression to HGD or cancer 
ranged from 2-16 years. 
The length of BO was 3-4 cm in 28 patients (27%), 5-9 cm in 49 patients (47%), and ≥ 10 
cm in 28 (27%) patients (Table III). The mean length of the BO was 8.5 cm in the 6 patients 
who had developed cancer in BO, and 8.6 cm in the group of 11 patients who had developed 
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HGD or adenocarcinoma, whereas the mean length of BO was 6.9 cm in the group of 94 
patients without HGD or adenocarcinoma. A trend towards cancer development was observed 
for increasing lengths of BO (P=0.06; Table III), with a significantly increased risk for 
progression to HGD or cancer (P=0.02; Table III).  
Two of 11 (18%) patients in whom HGD or adenocarcinoma was detected presented with 
an ulcer in BO at index endoscopy, compared with 36 in the other 94 (38%) patients. The 
difference in cancer incidence for the group with and without an ulcer in BO at entry was not 
significant (P=0.85; Table II). However, when progression to HGD was included in the 
analysis, a trend was observed (P=0.09; Table II). The presence of an ulcer in BO at index 
endoscopy was associated with a longer segment of BO. Seventeen of the 38 patients, 
presenting with an ulcer in BO at index endoscopy, had BO of longer than 10 cm, 15 had BO 
of 5-10 cm length, and 6 had BO of 3-5 cm (P=0.005; Table III). 
No differences in the occurrence of HGD/cancer or cancer alone were observed for gender 
(Table II). 
 
 
 
Table II. Risk factors for development of high-grade dysplasia (HGD)/cancer in 
 105 patients with Barrett’s oesophagus (BO) 
 
   HGD or cancer in BO  Cancer in BO 
 N (%)     p-value*     p-value* 
Ulcer in BO at intake 
Yes 38 (36)   6  0.09     2    0.85 
No 67 (64)   5       4 
 
Low-grade dysplasia in BO at intake 
Yes 11 (10)   2       1  
No 64 (61)   5  0.33    3    0.61 
Unknown 30 (29)   4       2 
 
Gender  
Male 58 (55)   7  0.17    3    0.51 
Female 47 (45)   4       3 
*Statistical analysis was performed using the Kaplan-Meier method (test: log-rank, 20-year 
incidence). 
HGD= high-grade dysplasia; BO= Barrett’s oesophagus. 
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Table III. Relationship between increasing length of Barrett’s epithelium and the 
presence of an ulcer at intake, or the development of high-grade dysplasia (HGD)/cancer 
during follow-up 
 
      Length of Barrett’s epithelium 
         3-4 cm      5-9 cm      ≥10 cm            p-value* 
         (n=28)      (n=49)      (n=28) 
Ulcer at intake   
Yes (%)           6 (21)       15 (31)      17 (57)    0.005 
No (%)      22 (79)          4 (69)      13 (43)  
 
Cancer + HGD 
Yes (%)          1 (4)           4 (8)            6 (21)    0.02 
No (%)         27 (96)       45 (92)        22 (79) 
 
Cancer 
Yes (%)         0 (0)          3 (6)           3 (11)      0.06 
No (%)       28 (100)     46 (94)        25 (89)  
* Statistical analysis was performed using the Kaplan-Meier method (test: log-rank, 20-year 
incidence).  
HGD=high-grade dysplasia. 
 
DISCUSSION   
By redefining the Rotterdam Barrett’s oesophagus cohort according to current standards 
requiring the histological presence of specialised intestinal metaplasia, we were able to obtain 
more accurate data on cancer incidence and mortality in BO. Adenocarcinoma in BO was 
detected in 6 out of 105 patients after a mean follow-up of 12.7 years. The total of six cancers 
in 1329 patient-years, resulting in one case of cancer in 221 patient-years in the redefined 
cohort, was not markedly different from the cancer risk of 1 in 180 patient-years found in our 
previous study (4). The incidence rate is comparable to those in recently published 
prospective studies, reporting one case of cancer in BO per 187 to 208 patient-years of 
follow-up (15,16). 
Five of 11 patients with HGD or cancer in BO had a potentially curative treatment. One of 
these patients, however, dies 3 months after surgery, of postoperative complications, whereas 
another patient died unexpectedly 4 years after surgery from liver metastastasis presumably of 
oesophageal origin. The remaining 6 patients were considered unfit for surgery because of 
advanced age or severe comorbidity (n=5), or refused surgery (n=1. Nine of 11 patients with 
HGD or carcinoma in BO had died at the end of follow-up at a mean age of 76 years, which 
was not different from the mean age of death in all 72 patients who had died at the end of 
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follow-up. Overall, 4/72 (6%) deaths at the end of follow-up were related to complications of 
sugical treatment for adenocarcinoma (n=1), or metastatic disease (n=3) after initial HGD or 
adenocarcinoma in BO.  
In a study from Scotland, MacDonald et al. (17) reported equally disappointing findings. 
Of 409 patients with BO, only 143 (35%) were considered suitable for surveillance. Five of 
these 143 patients developed oesophageal carcinoma; only one was detected during 
surveillance. This last patient died from postoperative complications.  
The guidelines from the American College of Gastroenterology  recommend a shortening 
in the interval of endoscopic surveillance when LGD is found (14). There is substantial intra- 
and interobserver variability in the diagnosis LGD (18). Skacel et al. (19) reported that 
agreement on the diagnosis LGD by experienced GI pathologists suggests an increased risk of 
progression from LGD to HGD or adenocarcinoma. They studied the clinical course of 25 
patients with a diagnosis of LGD in BO at index endoscopy. Five of their 25 patients 
developed HGD in BO (20%) and 2 (8%) developed adenocarcinoma after a mean follow-up 
of 11 months. LGD in BO at index endoscopy was found to be a risk factor for progression to 
HGD or adenocarcinoma in two other reports as well (20,21). In our cohort, 11 patients had 
LGD at baseline. An increased risk for neoplastic progression was not observed. However, 
during follow-up, 14 other patients had LGD detected. Of this total of 25 patients who ever 
had LGD, 6 (24%) patients progressed to HGD or cancer in BO, 2-16 years after the first 
diagnosis of LGD. This finding confirms that LGD in BO is probably a significant prognostic 
factor. Apart from that, the length of BO at index endoscopy in this cohort was found to be a 
risk factor for neoplastic progression. This was previously reported by our group (4,22) and 
also by Iftikhar et al. (23).  
An ulcer in BO at index endoscopy, found in 36% of the patients in this study, showed a 
trend (p=0.09) for progression to HGD and adenocarcinoma. Such ulcers were more 
frequently detected with increasing lengths of BO (P=0.02). In a multivariate analysis, a 
longer segment of BO appeared to be a more important risk factor than the finding of an ulcer 
in BO at index endoscopy.  
 In conclusion, presently, endoscopic surveillance is recommended for all patients with BO 
to detect early-stage neoplastic changes (14). This was recently supported by findings from 
three retrospective studies of patients with adenocarcinoma of the oesophagus and gastric 
cardia, in which a survival benefit was found for the 4-18% of patients who underwent an 
endoscopy some time before a cancer diagnosis was made (24-26). However, the results of 
our study show that both cancer incidence and mortality from it are low in patients with BO. 
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Therefore the benefit of surveillance in terms of life-years gained may be relatively small 
compared to the costs and resources involved. In our opinion, it is important to identify risk 
factors, including biomarkers, for malignant progression in Bo that can detect those patients 
most likely to benefit from surveillance. In this way, the cost-effectiveness of surveillance for 
BO is likely to be improved.  
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ABSTRACT 
 
Background: Photochemical and thermal methods are used for ablating Barrett’s oesophagus 
(BO). The aim of this study was to compare 5-aminolevulinic acid induced photodynamic 
therapy (ALA-PDT) with argon plasma coagulation (APC) with respect to complete reversal 
of BO.  
Methods: Patients with BO (32 no dysplasia and eight low-grade dysplasia) were randomised 
to one of three treatments: (a) ALA-PDT as a single dose of 100 J/cm2 at four hours 
(PDT100; n=13), (b) ALA-PDT as a fractionated dose of 20 and 100 J/cm2 at one and 4 
hours, respectively (PDT20+100; n=13) or (c) APC at a power setting of 65 Watt in two 
sessions (APC; n=14). If complete elimination of BO was not achieved by the designated 
treatment, the remaining BO was treated by a maximum of two sessions of APC. 
Results: Mean endoscopic reduction of BO at six weeks was 51% (range 20-100%) in the 
PDT100 group, 86% (range 0-100%) in the PDT20+100 group, and 93% (range 40-100%) in 
the APC-group (PDT100 v PDT20+100, p<0.005; PDT100 v APC, p<0.005; and PDT20+100 
v APC, NS) with histologically complete ablation in 1/13 (8%) patients in the PDT100 group, 
4/12 (33%) in the PDT20+100 group, and 5/14 (36%) in the APC group (NS). Remaining BO 
was additionally treated with APC in 23/40 (58%) patients. Histological examination at 12 
months revealed complete ablation in 9/11 (82%) patients in the PDT100 group, in 9/10 
(90%) patients of the PDT20+100-group, and in 8/12 (67%) patients in the APC group (NS). 
At 12 months, no dysplasia was detected. Side effects (that is, pain (p<0.01), and nausea and 
vomiting (p<0.05) and elevated liver transaminases (p<0.01) were more common after PDT 
than APC therapy. One patient died three days after treatment with PDT, presumably from 
cardiac arrhythmia. 
Conclusion: APC alone or ALA-PDT in combination with APC can lead to complete reversal 
of Barrett’s epithelium in at least two thirds of patients when administered in multiple 
treatment sessions. As the goal of treatment should be the complete reversal of Barrett’s 
epithelium, we do not recommend these techniques for the prophylactic ablation of BO. 
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Barrett’s oesophagus (BO) is a premalignant condition in which the normal squamous 
epithelium of the distal oesophagus is replaced by an incomplete form of intestinal 
metaplasia, named specialised intestinal metaplasia (1). Patients with BO have an age and sex 
related risk of 0.5% per year of developing adenocarcinoma of the oesophagus (2).  
 Current management of BO includes endoscopic surveillance at intervals determined by 
the presence of intestinal metaplasia and the grade of dysplasia within this epithelium (3). The 
rationale for this approach is that surveillance detects high-grade dysplasia (HGD) and 
oesophageal adenocarcinomas at an earlier stage, resulting in a more favourable outcome 
compared with carcinomas presenting with dysphagia (4).  
 A new approach includes the use of endoscopic ablative techniques in combination with 
antireflux therapy. These techniques can be used therapeutically to remove areas of HGD or 
early cancer and prophylactically to eliminate the specialised intestinal metaplasia and replace 
it by squamous epithelium. The currently available ablative modalities are based on 
photochemical (photodynamic therapy), thermal (argon plasma coagulation, laser, and 
multipolar electrocoagulation and heater probe) and mechanical (endoscopic mucosal 
resection) principles (5). 
 Photodynamic therapy (PDT) involves the light induced activation of an administered 
photosensitiser which leads to local injury by the production of singlet oxygen. The most 
commonly used photosensitiser is porfimer sodium (Photofrin) (6). A novel approach to PDT 
is endogenous photosensitisation with 5-aminolevulinic acid (ALA). ALA by itself has no 
photosensitising properties, but is metabolised to its photosensitising product protoporphyrin 
IX (7).  
 Argon plasma coagulation (APC) is a non-contact electrocoagulation procedure in which 
high frequency energy is transmitted to tissue by an ionised gas (argon gas). It induces the 
coagulation of a tissue thickness of up to 2-3 mm, resulting in the injury of the superficial 
layers of tissues (8). 
 Currently, all published studies on ablative therapy of BO have dealt with a single 
treatment modality. In addition, to our knowledge, there are no studies which have compared 
different techniques of endoscopic reversal of BO. We performed a randomised study 
comparing the efficacy of single or fractionated dose ALA-PDT with APC for the 
prophylactic reversal of BO in 40 patients with BO without dysplasia or with low-grade 
dysplasia (LGD). If complete elimination of BO was not achieved by the designated 
treatment, the remaining BO was ablated by additional APC. 
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Table 1 Demographic details of patients treated with single dose ALA-PDT (PDT100), 
fractionated dose ALA-PDT (PDT20+100) or APC 
 
 
       PDT100      PDT20+100   APC 
       (n=13)   (n=13)  (n=14) 
  
 
Age (y) (median (range))     57 (52-72)       61 (57-69)     60 (41-69) 
 
Sex (M/F)     10/3     10/3    11/3 
 
BO length (cm)      3 (2-5)         3 (3-4)       3 (3-4)  
(median (range)) 
 
Histology of BO 
No dysplasia    10         11     11 
LGD       3          2         3  
 
Follow-up in months      12 (9-18)        12 (6-24)          12 (9-21)  
(median (range)) 
 
Mean dose of omeprazole     46 (40-80)        45 (40-80)         51 (40-80) 
(mg) (median (range)) 
 
ALA, 5-aminolevulinic acid; APC, argon plasma coagulation; BO, Barrett’s oesophagus; LGD; low grade dysplasia; PDT, 
photodynamic therapy. 
No significant differences  between groups.   
  
 
PATIENTS AND METHODS 
Patients 
From January 2001 to July 2002, 40 patients with a BO length of 2-5 cm were enrolled into 
the study. Participation was restricted to patients with specialised intestinal metaplasia 
(Barrett’s metaplasia) and no more than LGD on histological examination. Written informed 
consent was obtained from all patients who were at least 18 years of age. The study was 
approved by the Institutional Review Board of the Erasmus MC Rotterdam, The Netherlands. 
All patients were taking proton-pump inhibitors (PPIs) for at least six months before 
treatment. Exclusion criteria were: intolerance to (repeated) endoscopy, pregnancy, acute 
porphyria, and intercurrent diseases precluding survival during the study period.  
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Treatment protocol  
All patients underwent baseline endoscopy within two months prior to treatment. The 
distribution of BO was recorded and the total length of BO was measured. Endoscopic 
photographs were taken at various levels and from different angles in the oesophagus and 
stored as JPEG-files. Four quadrant biopsies were taken at 2 cm intervals with a standard 
biopsy forceps. Biopsies were stained with haematoxylin-eosin, and in some cases with alcian 
blue at pH 2.5. All biopsies were reviewed by a single experienced gastrointestinal 
pathologist (HvD). Randomisation was performed by the trial centre of the Department of 
Internal Oncology, Erasmus MC Rotterdam. Patients were stratified for the presence of no 
dysplasia or LGD in baseline biopsies.  
 For ALA-PDT, 60 mg/kg ALA (Sigma-Aldrich Chemie BV, Zevenaar, The Netherlands) 
was dissolved in 20 ml of orange juice. All patients were kept in a darkened room for 36 
hours after ingestion. Blood cell counts and liver enzymes levels were determined at baseline 
and the day after treatment. A KTP/532-dye laser module (Laser scope, San Jose, California, 
USA) delivered light with a wavelength of 630 nm. PDT illumination schemes were: (a) a 
single laser illumination with a fluence (light dose) of 100 J/cm2 at four hours after ALA 
administration (PDT100 group) or (b) a fractionated laser illumination with a fluence of 20 
J/cm2 and 100 J/cm2 at one and four hours, respectively, after ALA administration 
(PDT20+100 group). Light delivery was performed using an inflatable balloon with an 
inflated diameter of 2.5 cm (Wizzard X-cell, Wilson-Cook Medical, Inc., Winston-Salem, 
North Carolina, USA). The total output power of the cylindrical diffuser (400 µm fibre core 
diameter) (CeramOptec, GmbH, Bonn, Germany) was measured in an integrating sphere 
(Grasbery Optronics S370; TeLintelo Systems, The Netherlands) and was set to a value 
yielding a calculated fluence rate of 100 mW/cm2 (9). The cylindrical diffuser was aligned in 
the balloon prior to the procedure. The length of the window of the balloon and the cylindrical 
diffuser were either 3 or 5 cm, depending on the estimated length of BO. The deflated balloon 
was positioned over a guide-wire and its position was checked endoscopically. The output 
power of the cylindrical diffuser was checked prior to and post ALA-PDT. 
 For APC, an Argon Beamer 2 device, APC 300 (Erbe Medizintechnik, Tübingen, 
Germany) was used with a gas flow rate of 2 L/min at a power setting of 65 W. We aimed to 
ablate two thirds of the oesophageal circumference of BO during the first session, while in the 
following session the remainder of the BO was ablated. Ablation was initiated at the gastro-
oesophageal junction and than proceeded longitudinally towards the proximal 
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squamocolumnar junction. APC comprised a maximum of two treatment sessions per patient 
at four week intervals. 
 
Follow-up protocol 
Patients were treated with a daily dose of at least 40 mg omeprazole (AstraZeneca, 
Zoetermeer, the Netherlands). Both patients and their general practitioners were instructed 
that this dose of PPI needed to be continued during the study. Patient symptoms during and 
after ablation therapy were recorded. In addition, patients were contacted by telephone on day 
5 after treatment to assess side effects.     
 Follow-up endoscopies were performed at six weeks and at 6, 12, 18 and 24 months after 
ablative treatment. During follow-up endoscopies, photographs were taken and stored as 
JPEG-files. In addition, biopsies were taken from all four quadrants at 2 cm intervals 
throughout the BO segment. Endoscopic pictures were assessed by two investigators (PDS, 
MH) who were blinded to the treatment that the patient had received. On histological 
examination, samples were scored for the presence or absence of specialised intestinal 
metaplasia and, if present, whether this was found next to or underneath (regenerated) 
squamous epithelium. In addition, the highest grade of dysplasia was recorded.  
 If macroscopic BO was observed at the first follow up endoscopy at six weeks after 
treatment, this BO was ablated by additional APC with a maximum of two sessions at four 
week intervals.      
 Results were expressed as: 1) endoscopic reduction of the BO surface and 2) microscopic 
presence or absence of Barrett’s metaplasia, at six weeks and at 6, 12, 18 and 24 months after 
the initial treatment.  
 
Statistical analysis 
Endoscopic reduction of the BO surface was compared between the PDT100 group, the 
PDT20+100 group and the APC-group using Mann-Whitney U tests between all three 
possible comparisons. Adjustment for multiple comparisons was not performed, since all 
three comparisons were considered to be of interest. Patient demographics, histological results 
and symptoms after ablative treatment were compared using the χ2 test. A difference was 
considered significant if p<0.05. 
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Table 2 Microscopical evaluation at six weeks after treatment in patients treated with single 
dose ALA-PDT (PDT100; n=13), fractionated dose ALA-PDT (PDT20+100; n=12) or APC 
(n=14) 
 
   No BO   Residual BO  Sub-squamous BO 
 
PDT100    1        12     0 
PDT20+100    4        7      1 
APC    5        4*     5 
 
ALA, 5-aminolevulinic acid; APC, argon plasma coagulation; BO, Barrett’s oesophagus; PDT, photodynamic therapy. 
*Two of these patients also had sub-squamous BO 
No significant differences between the groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
Endoscopic reduction of Barrett’s oesophagus at six weeks after treatment, in patients given single dose 5-aminolevulinic acid (ALA)-
photodynamic therapy (PDT) (PDT100; n=13), fractionated dose ALA-PDT (PDT20+100; n=12), and argon plasma coagulation (APC) 
(n=14). PDT100 group v PDT20+100 group, p,0.005; PDT100 group v APC group, p<0.005; PDT20+100 group v APC group, NS 
 
 
 
 
 
 
Endoscopic reduction of Barrett’s esophagus 
(%)
0
20
40
60
80
100
PDT100 PDT20+100 APC
Chapter 3 
58 
RESULTS 
Forty (31 males/nine females) patients with a mean BO length of 3 cm (range 2-5) and no 
dysplasia (n=32) or with LGD (n=8) on histological examination were included. Median age 
of all patients was 59 years (range 41-72). The mean dose of omeprazole after treatment was 
47.5 mg (range 40-80). The three patients groups were demographically similar (table 1).   
 All patients completed the designated ablative therapy. Of the 26 patients treated with 
ALA-PDT, 24 (96%) showed endoscopic reduction of BO at six weeks after treatment (fig 1). 
One patient treated with a fractionated dose of PDT showed no response and another patient 
treated with a fractionated dose of PDT died shortly after treatment (see below). Mean 
endoscopic BO surface reduction was 51% (range 20-100%) in the PDT100 group and 86% 
(range 0-100%) in the PDT20+100-group. No endoscopic evidence of remaining BO was 
seen in one (8%) patient of the PDT100 group and in five (42%) patients of the PDT20+100 
group. All 14 patients treated with APC showed endoscopic reduction of BO at six weeks 
after treatment. Mean endoscopic regression was 93% (range 40-100%). No endoscopic 
evidence of remaining BO was seen in seven (50%) patients in the APC group (PDT100 
group v PDT20+100-group, p<0.005; PDT100 group v APC group, p<0.005; PDT20+100 
group v APC group, NS).  
 Histological evaluation at 6 weeks after treatment revealed complete reversal of BO in one 
(8%) patient of the PDT100 group, in four (33%) patients of the PDT20+100 group and in 
five (36%) patients of the APCgroup (NS). The presence of BO after treatment was 
predominantly found as BO next to (regenerated) squamous epithelium in both PDT groups. 
In the APC group, BO was found as BO underneath squamous epithelium (sub-squamous 
BO) in 7/9 patients (table 2). 
 All patients with macroscopic BO at the follow up endoscopy at six weeks received 
additional APC treatment in one (20 patients) or two (three patients) sessions (fig 2). Follow 
up endoscopy at six months showed macroscopic BO in one (7%) patient in the APC group 
(table 3), whereas histological evidence of BO was found in one patient in the PDT100 group 
and in three patients in the APC group. Endoscopic presence of BO at 12 months was 
observed in one patient in the PDT100 group and in two (17%) patients in the APC group. 
Histological examination at 12 months revealed BO in two patients in the PDT100 group, in 
one patient in the PDT20+100 group and in four patients in the APC group. Endoscopic BO at 
18 months was observed in two patients in the PDT100 group and in two patients in the APC 
group, whereas histological evidence of BO was found in two patients in the PDT100 group, 
ALA-PDT versus APC for ablation of Barrett’s oesophagus 
59 
in one patient in the PDT20+100 group, and in three patients in the APC group. During follow 
up, no dysplasia was observed in any of the biopsies with remaining BO. 
 Side effects are shown in table 4. Pain during treatment, and nausea and vomiting were 
more common in patients treated with ALA-PDT compared with APC. One patient treated 
with APC developed a stricture which was effectively treated by a single session of dilation. 
Another patient treated with a fractionated dose of ALA-PDT died suddenly three days after 
treatment. This patient had left the hospital one hour earlier and had not reported clinical 
symptoms at the moment of departure. At autopsy, the oesophageal wall showed microscopic 
signs of transmural necrosis without perforation. Although an atherosclerotic change of the 
arterial blood vessels was observed, no evidence of an ischaemic cardiovascular event was 
found. The autopsy revealed no clear explanation for the sudden death in this patient. Twenty 
patients treated with ALA-PDT had a mild elevation of transaminase levels the day after 
treatment (aspartate aminotransferase: mean 62 U/L (range 39-89) (reference 5-30 U/L); 
alanine transferase: mean 72 U/L (range 51-116) (reference 10-40 U/L). At six weeks, liver 
enzyme levels in all patients had normalised.  
 
 
 
 
 
Figure 2 
Endoscopic views of a patient with Barrett’s oesophagus (BO): (A) before treatment, (B) 80% reversal of BO at six weeks after treatment 
with a fractionated dose of ALA-PDT, and (C) complete reversal of BO at six months after additional treatment with argon plasma 
coagulation.  
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Table 3  Barrett’s oesophagus during follow up in patients treated with single dose ALA-PDT 
(PDT100), fractionated dose ALA-PDT (PDT20+100) or APC, in some patients followed by 
treatment with APC for residual Barrett’s oesophagus. 
 
 
Follow-up  PDT100 group     PDT20+100 group      APC group 
(months) 
  Endoscopic  Histological Endoscopic  Histological Endoscopic   Histological 
  BO (%)   BO (%)  BO (%)   BO (%)  BO (%)      BO (%) 
 
6  0/13    1/13 (8) 0/12   0/12   1/14 (7)   3/14 (21) 
  
12  1/11 (9)    2/11 (18) 0/10    1/10 (10)  2/12 (17)     4/12 (33)  
 
18  2/8 (25)    2/8 (25) 0/8     1/8 (12)  2/9 (22)      3/9 (33)  
 
24  NA1      NA  0/2     0/2    NA      NA 
 
1NA, not applicable 
ALA, 5-aminolevulinic acid; APC, argon plasma coagulation; BO, Barrett’s oesophagus; PDT, photodynamic therapy. 
No significant differences between the groups 
 
Table 4 Side effects and complications in patients treated with ALA-PDT (single dose and 
fractionated dose combined) or APC 
 
 
          PDT (n=26)     APC (n=14)    p Value 
 
Pain during treatment      23        5      <0.01 
Odynophagia         24        12      NS 
Fever           8         2      NS 
Nausea and vomiting      7           0     <0.05 
Sudden death         1*        0     NS 
Stricture formation       0         1     NS 
Elevated liver enzyme tests   20        0     <0.01  
 
ALA, 5-aminolevulinic acid; APC, argon plasma coagulation; PDT, photodynamic therapy. 
*patient died presumably from cardiac arrhythmia 
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DISCUSSION 
This is the first study in which a photochemical method for removing BO (that is, ALA-PDT) 
was compared with a presently available thermal modalitiy (that is, APC) for the prophylactic 
reversal of Barrett’s intestinal metaplasia to squamous epithelium. 
Single treatment with ALA-PDT and APC initially reduced the total surface of BO by 96% 
and 100%, respectively (fig 1). However, complete elimination of BO was seen in only five of 
25 (20%) patients treated with ALA-PDT alone and in five of 14 (36%) patients treated with 
two sessions of APC at 6 weeks after treatment (table 2). After subsequent treatment with 
APC in patients with persistent BO at the first follow up endoscopy at six weeks, complete 
microscopic reversal was obtained in 18 of 21 (86%) patients in both ALA-PDT-groups and 
in eight of 12 (67%) patients in the APC-group at 12 months after the initial treatment (table 
3). In patients with residual BO, no evidence of dysplasia was found. 
 How do our results compare with other studies? Two larger studies on the use of ALA-
PDT for BO have been published. One therapeutic study by Gossner and colleagues (10) 
reported eradication of HGD in BO in all 10 patients and elimination of intramucosal cancer 
in 17 of 22 patients, mostly after two separate ALA-PDT treatments. Squamous re-
epithelialisation was observed in only two thirds of patients and was incomplete in all of 
them. In another study by Ackroyd and colleagues (11), 18 patients with LGD in BO were 
treated by one session of ALA-PDT. The median decrease in the surface of BO was 30%, and 
none of the control biopsies from remaining Barrett’s epithelium showed dysplasia.  
 We applied two different PDT illumination schemes: (a) a single illumination scheme 
with an energy dose of 100 J/cm2 at four hours, and (b) a fractionated illumination scheme 
with an energy dose of 20 J/cm2 and 100 J/cm2 at one and four hours, respectively, after ALA 
ingestion. The latter scheme was chosen because our previous experimental work had shown 
that a fractionated ALA-PDT scheme increased cell death in human EBV transformed cell 
lines. We demonstrated that an early course of ALA-PDT inhibited the haeme biosynthetic 
enzyme ferrochelatase, while the activity of another rate limiting enzyme, porphobilinogen 
deaminase, remained intact. This resulted in an increased accumulation of the photosensitiser 
protoporphyrin IX and an increased efficacy of a second course of ALA-PDT (12). There is 
however no agreement in the literature whether a fractionated illumination scheme enhances 
the therapeutic effect of PDT (13,14). In agreement with our experimental results, we found 
that the fractionated dose of ALA-PDT led to a more pronounced regression of BO at six 
weeks than the single dose, both macroscopically (fig 1) and microscopically (table 2), 
although the latter did not reach statistical significance.   
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 The use of APC for reversing BO has been reported in several studies (15-22). In these 
studies, complete reversal of BO ranged from 42% to 98% after 1-6 treatments with APC. In 
our study, 67% of the patients had a complete histologic response one year after 2 to 4 
treatment sessions with APC (table 3). This somewhat disappointing result can, at least in 
part, be explained by our strict definition of persistent BO, according to which any biopsy 
showing specialised columnar epithelium was considered to be persistent BO. Islands of BO 
underlying newly formed squamous epithelium were found in 7/9 patients with an incomplete 
response after the initial treatment with APC. Sub-squamous islands of BO were more often 
found after APC (50%) than after ALA-PDT (4%) (table 2), which is in accordance with 
findings by others (10,21). Sub-squamous BO may regress or remain clinically unimportant if 
protected by the newly formed squamous epithelium from repeated attacks by gastric and 
duodenal fluid. However, there are reasons to believe that these islands retain their malignant 
potential. At least two cases of adenocarcinoma arising under the newly formed squamous 
epithelium have been reported after APC (23,24).  
 It has been suggested that the results of APC can be improved by using a power setting of 
65 W or more. Higher power APC settings may result in deeper tissue destruction and 
therefore more complete ablation of BO (17,18). In addition, recurrence of BO after APC was 
found to be related to the presence of a long segment of BO (>3 cm) and to persistent acid 
reflux as measured by pH monitoring and/or a reduction of PPI dose (21,22). In our study, we 
performed APC at a power setting of 65W, the median length of BO was 3 cm, and the mean 
daily dose of omeprazole was 45 mg in the APC treatment group. As oesophageal pH 
monitoring was not performed in our study, we can not exclude the fact that incomplete 
ablation of BO may also be explained by  higher exposure to pH levels <4 in these patients.  
 Until a few years ago, the main goal of ablative therapy was the histological downgrading 
of dysplasia. Recent studies have however demonstrated that genetic abnormalities can persist 
in BO after ablative therapy (25,26). In addition, van Hillegersberg and colleagues (27) 
recently described two patients who developed adenocarcinoma after incomplete endoscopic 
ablation of Barrett’s epithelium. Therefore, the goal of treatment should be the complete 
elimination all Barrett’s metaplastic tissue. Whenever macroscopic BO was observed at the 
first follow-up endoscopy at six weeks, we treated this with additional APC resulting in a 
further increase in the number of patients macroscopically and microscopically free of BO at 
12 months of follow up. However, of the more than 60% of patients followed up for 18 
months, 12-33% were still found to have BO next to or underneath the regenerated squamous 
epithelium (table 3). Therefore, the injury produced by ALA-PDT, APC, or the combination 
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of both was not sufficient to completely reverse BO in all patients. As BO is thought to 
originate from cells in the deeper layers of the oesophageal wall (28), it may be well that, 
even after complete reversal of the Barrett’s epithelium, and in the presence of persistent acid 
reflux, recurrent growth of BO is more successful than squamous regeneration.  
 One of the reasons why the photosensitiser ALA has become more popular than Photofrin 
in Europe is its presumed lower incidence of side effects. We saw no skin photosensitivity 
after ALA-PDT. In contrast, owing to its long half-life, patients are advised to avoid sun (UV) 
light for a period of 4-6 weeks after being treated with Photofrin. No strictures were observed 
in our patients treated with ALA-PDT, while strictures have been reported in 34% of patients 
given Photofrin (6). Severe chest pain during treatment was an important side-effect of ALA-
PDT, necessitating the use of high doses of analgesics (table 4). Another (transient) side effect 
of ALA-PDT was a two- to threefold increase in transaminase levels, reflecting liver 
parenchyma damage. Independent of the presence of light, a local autocatalytic interaction 
between ALA, iron, and oxygen has been demonstrated in the liver, which could be 
responsible for the parenchyma-specific increase in liver enzymes (29). Finally, an 
unexpected finding was a sudden death in a patient who was treated with a fractionated dose 
of ALA-PDT three days before his death. He had no clinical symptoms when leaving the 
hospital, and collapsed one hour after having been discharged. Autopsy showed microscopic 
signs of transmural necrosis of the oesophageal wall at the site where the treatment had been 
performed but no evidence of perforation or mediastinal inflammation. In an earlier study, we 
also observed necrosis of the layers of the oesophageal wall in rats treated with PDT. None of 
these rats developed a perforation of the oesophagus (30). A possible explanation for the 
unexpected death in this patient may have been a cardiac arrhythmia. Atrial fibrillation has 
been reported during and following oesophageal PDT (31,32).  
 In conclusion, APC alone or ALA-PDT in combination with APC can lead to complete 
reversal of Barrett’s epithelium in at least two thirds of patients when administered in multiple 
treatment sessions. Single modality treatment (ALA-PDT alone or APC in two sessions) 
resulted in the persistence of BO in the majority of patients even when the immediate post-
treatment macroscopic appearance suggested adequate treatment. We were not able to show a 
significant difference in efficacy between both treatments. Treatment with ALA-PDT was 
accompanied by more side effects than APC. Since the goal of treatment should be the 
complete reversal of Barrett’s epithelium to squamous epithelium, we do not recommend 
these techniques for the prophylactic ablation of BO. 
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ABSTRACT  
 
Barrett’s oesophagus is a major risk factor for developing oesophageal adenocarcinoma. 
Ablation by argon plasma coagulation (APC) and photodynamic therapy (PDT) is currently 
under investigation for removal of metaplastic and dysplastic BE. This study examined the 
effect of ablative therapy on Barrett’s oesophagus at the cell-cycle and genetic levels. The 
premalignant potential of residual or recurring Barrett’s oesophagus was assessed  by p53 
immunohistochemistry, Ki67-related proliferative capacity, and DNA ploidy status (i.e. 
abnormal chromosome 1 number) as measured by interphase in situ hybridization. Twenty-
nine patients with Barrett’s oesophagus (23 male and 6 female, mean age 58 years, mean 
length of Barrett’s oesophagus 4 cm) were treated with APC or PDT. Intestinal metaplasia 
without dysplasia was present in 16 patients, low-grade dysplasia in 5, and high-grade 
dysplasia in 8 patients. Biopsy samples were obtained at regular intervals (mean follow-up: 20 
months, range 6-36 months). One month after the first ablation, Barrett’s oesophagus was no 
longer identified, either endoscopically or histologically, in nine patients (32%). At this time 
point, significant down-grading was achieved for abnormal chromosome 1 numbers (p = 
0.020) and Ki67-defined proliferation (p = 0.002). Patients with residual BE were additionally 
treated with APC, resulting in the elimination of Barrett’s oesophagus in 76% of all patients. 
However, at the last follow-up endoscopy metaplasia without dysplasia was still present in 
five patients, and low- and high-grade dysplasia were each present in one patient. An 
abnormal chromosome 1 number and p53 protein overexpression were detected only in the 
high-grade dysplastic lesion, but increased proliferation was still present in the majority of 
these persisting cases. Although endoscopical removal of Barrett’s oesophagus by ablative 
therapies is possible in the majority of patients, histologically complete elimination can not be 
achieved in all cases. Persisting Barrett’s oesophagus may still harbour molecular aberrations 
and must therefore be considered still to be at risk for  progression to adenocarcinoma. 
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Barrett’s oesophagus (BO) is a major predisposing factor for the development of  oesophageal 
adenocarcinoma. In BO, the normal squamous epithelial lining of the esophagus is replaced 
by specialised columnar lined epithelium under the influence of long-standing and severe 
gastro-esophageal reflux (GORD). In the last two decades, the incidence of oesophageal 
adenocarcinoma has increased (1,2). The rate of developing oesophageal adenocarcinoma is 
approximately 0.5% per year in patients with BO [3]. Malignancy in BO arises through the 
multi-step histological sequence of Barrett’s metaplasia (MET), low-grade dysplasia (LGD), 
high-grade dysplasia (HGD) and finally adenocarcinoma (4). Currently, patients with BO 
undergo periodic surveillance endoscopy to detect dysplastic changes at an early stage.  
When BO has evolved to HGD, oesophagectomy is often the treatment recommended to 
patients. However, surgical intervention is not an option in a subset of patients because of 
severe co-morbidity, or because they are unwilling to undergo oesophageal resection. In the 
last decades, several groups have applied endoscopic techniques to ablate BO to decrease or 
even eliminate the risk of neoplastic progression towards cancer (5-14). Argon plasma 
coagulation (APC) is a popular thermal technique and is available in many centres. Success 
rates ranging from 42-98% have been reported after a mean of one to six sessions (5-9). 
Ablation of BO by photodynamic therapy (PDT) is also successful in eliminating dysplasia 
(10,11). Complete removal of BO with or without dysplasia has been described using 5-
aminolevulinic acid (5-ALA-) induced PDT (12-14). Furthermore, long segments of BO can 
be eradicated by one session of ALA-PDT without the risk of developing strictures. Several 
groups, however, observed that Barrett’s glands are still present after treatment with APC or 
PDT. Moreover, these glands are sometimes buried underneath regenerated squamous 
epithelium. It is currently unknown whether residual or recurrent (dysplastic) BE has an 
increased risk of developing adenocarcinoma (9,12,14).  
Cell biological markers have been studied in the progression of BO to adenocarcinoma. 
Malignant progression has been assessed by determining cell cycle parameters and by studying 
growth factors. For example, the growth fraction was studied by staining for the proliferative cell 
nuclear antigen or Ki67 (15,16). These investigators found a high proportion of cycling cells in 
intestinal type epithelium with expansion of the proliferative compartment. Reid et al. [17] 
documented by flow cytometry that cell cycle abnormalities occur in the development of 
adenocarcinoma in Barrett's oesophagus. Moreover, polyploidy and aneuploidy have been 
reported as an early event in Barrett’s oesophagus (18,19). We previously reported that DNA 
in situ hybridization with a chromosome 1-specific centromeric probe revealed an increasing 
degree of aneuploidy along with the advancing stages towards neoplasia (16). Alteration of the 
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p53 tumour suppressor gene is likely the most frequent genetic lesion in Barrett’s esophagus 
and adenocarcinoma. This is caused by either mutation or loss of heterozygozity (LOH) of 
17p.  In metaplastic BO p53 protein overexpression is observed in few cases, whereas p53 
accumulation increases dramatically during progression from LGD to HGD (20,21).  
Recently, Reid et al. (22) demonstrated that 17p LOH was a predictor of cancer progression: 
20 of 54 patients with 17p LOH at base line developed cancer, as compared with only 6 of 
202 patients without loss. All these data suggest that, in BO, cytogenetic perturbations may be 
generated in relation to a high proliferation rate.  
The aim of this study was to investigate the effect of ablation therapy at both cell-cycle and 
genetic levels. Patients were followed at regular intervals after ablative therapy with  either 
ALA-PDT, APC, or both. BO biopsy specimens obtained before and after  treatment were 
analysed. Chromosome 1 number was assessed by DNA in situ hybridization and the 
proliferative capacity and p53 protein status were defined by immunohistochemistry.  
 
 
MATERIAL AND METHODS 
Patients 
Between April 2000 and August 2002 29 patients were enrolled in this study. The mean age 
of the patients was 58 years (range 37-79 years). The following inclusion criterium was 
applied: endoscopical BE with specialized intestinal metaplasia on histological examination. 
Before ablative therapy 16 patients had metaplasia (MET), 5 patients had low grade dysplasia 
(LGD) and 8 patients had high grade dysplasia (HGD). The mean length of the Barrett's 
segment was 4 cm (range 2-8 cm). Our hospital is both a clinic for primary treatment of 
patients with BO and a referral centre for patients with HGD in the south-west region of the 
Netherlands. The study thus consisted of two arms, the first containing patients with MET and 
LGD [14] and the second including patients with HGD. Exclusion criteria were: (1) 
pregnancy, (2) acute porfyria, (3) age below 18, and (4) severe comorbidity. All patients were 
randomized and treated with APC or ALA-PDT. The treatment characteristics are listed in 
Table 1. Patients were advised to take at least 40 mg omeprazol daily to obtain maximal acid 
suppression (AstraZeneca, Zoetermeer, The Netherlands). Written informed consent was 
obtained from all patients and the study was approved by the Institutional Review Board of 
the Erasmus MC Rotterdam. 
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Treatment & follow-up 
Treatment was preceded by base line endoscopy to determine the extent of the Barrett’s 
epithelium. Four-quadrant biopsy specimens for histological examination were taken at 1-cm 
intervals in patients with known HGD and at 2-cm intervals in all other patients. Patients 
receiving PDT (n=19, 66%) were pre-treated with the photosensitizer 5-ALA (Sigma-Aldrich 
Chemie BV, Zevenaar, The Netherlands) 60 mg/kg orally, 4 hours before application of light 
with a wavelength of 630 nm with a KTP/532 dye laser module (Laser scope, San Jose, 
California, USA). Light was administered via an endoscopically placed balloon (Wizzard X-
cell, Wilson-Cook Medical Inc, Winston Salem, North Carolina, USA). A dose of 1x100 
J/cm2 was given. Residual BE was treated with APC. For APC an Argon Beamer 2 device 
was used with a coagulation power setting of 65W and an argon gas flow rate of 2.0 l/min 
(Erbe Medizintechnik, Tűbingen, Germany). Patients receiving APC alone (n=10, 34%) were 
initially treated in two sessions, with a one-month interval between sessions. If macroscopic 
BE was observed after two sessions additional APC was performed until all visible BE was 
cleared. 
The therapeutic effect was evaluated endoscopically and histologically after 1 month,  and 
then at 3-months intervals, and after 1 year at 6-months intervals. Sampling was performed at 
1-cm intervals with four-quadrant biopsies from the treated area and from any residual 
macroscopic focus of BE present. Methylene blue staining was used to better identify residual 
BE. An extra specimen in the cardiac region of the stomach was obtained to serve as a control 
for immunohistochemical and cytogenetic analysis. All biopsies were formalin-fixed and 
paraffin wax-embedded, and stained with haematoxylin & eosin. All histological diagnoses 
were made using standard criteria by an experienced gastro-intestinal pathologist (HvD). 
 
Immunohistochemistry 
Formalin-fixed, paraffin wax-embedded, 4 µm consecutive tissue sections were mounted on 
aminoacetylsilane (AAS) coated slides (Starfrost, Berlin, Germany). Immunostaining was 
performed using the UltraVision Large Volume Detection System Anti-Polyvalent, HRP 
(Labvision, Fremont, CA), as described before by us [16,23]. After dewaxing, microwave 
(700 W) pretreatment was performed for 15 minutes using citrate buffer (10mM citric acid 
monohydrate, pH 6.0). To assess overexpression of the p53 protein, the primary antibody DO-
7 (DAKO, Glostrup, Denmark) was used, diluted 1/50 in phosphate-buffered saline (PBS)/5% 
BSA. To estimate proliferation rate primary labelling of the Ki67 antigen was performed with 
the monoclonal antibody Mib-1 (Immunotech, Marseille, France), diluted 1/100 in PBS/5% 
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BSA. A cytokeratin 8/18 antibody was used as a positive control, the primary antibody was 
omitted as a negative control.  
Moderate or intense brown nuclear staining was considered positive for both immunostains. 
In the base line biopsy samples the percentages of both p53 and Ki67 positive cells were 
established by serial counting of at least 200 cells in a previously assigned area of metaplasia 
or dysplasia in BE. After ablative treatment, the percentage of positively staining cells was 
determined in (foci of) residual or recurrent Barrett’s mucosa. Scoring was in all cases 
performed by two independent investigators. For p53 a percentage exceeding 15% of positive 
cells was regarded as overexpression of the p53 protein: 16-40% moderate (+), and >40% 
strong (++) overexpression. For Ki67 the percentage of positive cells was, if possible, 
determined in longitudinally sectioned crypts and villi. A percentage >20% was regarded as 
increased proliferation: 21-50% moderately (+), and >50% strongly (++) increased. These 
cut-off values were based on p53 and Ki67 stainings of normal gastric cardia controls. 
 
DNA in situ hybridiation  
The DNA ploidy status was determined by in situ hybridization (ISH) with a chromosome 1-
specific DNA probe to 2 µm thick dewaxed tissue sections mounted on AAS slides. This 
section thickness was chosen to minimize nuclear overlap and to facilitate counting. The 
(peri)centromeric DNA probe for chromosome 1 was labeled with digoxigenin-16 dUTP 
(Boehringer Mannheim, Indianapolis, IN) by nick translation (Gibco BRL, Gaithersburg, 
MD). The ISH procedure was carried out, as described before by us (16,24,25). Briefly, after 
appropriate pepsin digestion the sections were heat-denatured for 2 min in 70% formamide in 
2x SSC, and hybridized overnight at 37ºC with the denatured probe in a hybridization mixture 
containing 2 ng/µl DNA probe, 500 ng/µl herring sperm DNA (Sigma, St. Louis, MO), 0.1% 
Tween-20, 10% dextran sulphate, and 60% formamide in 2x SSC at pH 7.0. Then a series of 
stringent washes followed to remove the unbound probe. Histochemical detection was 
performed by immunoperoxidase staining. Slides were subsequently incubated with 
peroxidase-conjugated anti-digoxigenin antibodies (DAKO). The probe-related ISH signals 
were developed with diaminobenzidine (DAB), and the slides were counterstained with 
haematoxylin. The DNA probes were evaluated in a predefined tissue area. Up to 100 non-
overlapping nuclei were counted by two independent investigators and the number of solid 
DAB spots per nuclear contour was scored (0, 1, 2, 3, 4, >4 spots/ nuclear slice). The DNA 
probe spot distributions were then compared and averaged. In our series no discrepancies 
between the two investigators were encountered using this procedure. Leukocytes and 
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squamous epithelium on the same sections served as controls for hybridization quality. 
Aneuploidy (hyperdiploidy) was defined as >1.5% of the counted nuclei with more than 2 
ISH spots: 2-10% moderate (+), and >10% severe (++) aneuploidy. This cut-off value was 
based on gastric cardia control tissues (n=5; average percentage of cells with more than 2 ISH 
spots 0.3; SD 0.27), where the percentage of cell nuclei with an abnormal chromosome 1 
number never exceeded 1%. 
 
Statistics 
The Wilcoxon Signed Ranks Test was applied for comparisons of the immunostaining and 
ISH results between t=0 and t=1 month groups. The number of patients at the last endoscopy 
was too small for statistical analysis. P=0.05 (two-tailed) was taken as the limit of significanc 
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Table 1. Patients’ characteristics, treatment modality and length of follow-up. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 
ID 
Age 
(years) 
Sex Segment 
length of 
BE (cm) 
Histology
Therapy 
modality 
Length of 
follow-up 
(months) 
1 59 M 5 MET PDT  30 
2 59 M 4 MET PDT  24 
3 67 M 4 MET PDT  30 
4 44 M 3 MET PDT 24 
5 55 M 3 MET APC 24 
6 45 M 4 MET PDT 30 
7 51 M 4 MET PDT 24 
8 50 M 5 MET PDT  18 
9 55 M 5 MET PDT 24 
10 63 M 3 MET PDT 12 
11 54 M 4 MET PDT 18 
12 71 M 4 MET PDT 12 
13 37 M 2 MET APC 12 
14 51 F 4 MET APC 12 
15 53 F 5 MET PDT 9 
16 51 F 4 MET PDT 9 
17 39 F 4 LGD APC 6 
18 48 M 4 LGD APC 24 
19 66 M 4 LGD PDT 24 
20 62 M 3 LGD PDT 24 
21 59 M 5 LGD APC 18 
22 45 F 5 HGD PDT 36 
23 66 M 5 HGD APC 36 
24 75 M 4 HGD PDT 30 
25 74 M 3 HGD PDT 30 
26 54 M 4 HGD APC 30 
27 74 F 8 HGD APC 24 
28 79 M 3 HGD PDT 9 
29 73 M - HGD APC 9 
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RESULTS 
Twenty-nine patients, 23 male and 6 female, were treated with ALA-PDT or APC (Table 1). 
At the first follow-up endoscopy, ie 1 month after treatment, histological removal of BE was 
achieved in 9 of 28 patients (32%; one case not available). Patients with residual BE were 
additionally treated with APC resulting in eliminating BE in 22 of the 29 patients (76%). At 
this last time point residual or recurrent non-dysplastic BE was detected in five patients, LGD 
in one patient and HGD also in one patient. In 4 of these patients (including the LGD case) 
BE was found underneath squamous epithelium.  
We investigated residual or recurring BE by immunohistochemistry (IHC) and DNA in situ 
hybridization (ISH) of the dewaxed formalin-fixed tissue sections. Proliferative capacity was 
examined by immunostaining of Ki67 and premalignant potential was asessed by IHC of p53. 
DNA ploidy status (hyperploidy) was measured by interphase ISH with a chromosome 1-
specific repetitive DNA probe. Examples of IHC and ISH are shown in Figure 1, the 
experimental data are summarized in Table 2. Before treatment an abnormal chromosome 1 
number was detected in all evaluated HGD and LGD cases, and in 38% of MET samples 
(Table 2). All HGD and LGD specimens showed increased Ki67 proliferation rates, whereas 
this was detected in 86% of MET cases. P53 protein overexpression was found in 86% of the 
HGD samples, in none of the LGD cases, and in 14% of MET specimens (Table 2 and Figure 
2). One month after the initial ablation sessions an abnormal chromosome number was found 
in 7% of the patients with residual or recurring BO. Ki67 overexpression was seen in 71%, 
whereas overexpression of p53 was observed in 18% of these remaining BO samples (Table 2 
and Figure 2). Significant downgrading was achieved for abnormal chromosome 1 numbers 
(P = 0.020) and aberrant proliferation (P = 0.002), but not for p53  overexpression (P = 
0.119). Patients with residual or recurring BO were additionally treated with APC. However, 
at the last follow-up endoscopy, MET was still present in five patients, and LGD and HGD in 
1 patient each. Both an abnormal chromosome 1 number and p53 protein overexpression were 
detected in the HGD case only, but increased proliferation rates were measured in 67% of the 
patients with persisting BO (Table 2). Figure 2 shows that despite intensive ablative therapy 
metaplastic cells with increased proliferative capacity and genetic perturbations were still 
present or recurred at the last endoscopy. It appears that these BO cells may still carry the cell 
biological make-up for malignant progression. This is illustrated by case 22, in which 
recurrent HGD was detected 3 years after treatment for HGD, and repeated complete 
macroscopic and microscopic elimination of BO at earlier endoscopies. 
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DISCUSSION 
There is evidence that Barrett’s oesophagus is associated with an increased risk of developing 
oesophageal adenocarcinoma (26). Although the risk is highest in patients with (diffuse) 
HGD, patients with MET and LGD are also at an increased risk (27). It has been speculated 
that ablative therapies could reduce or even eliminate the risk of malignant progression (28). 
Until now, ablative therapies have been shown to be successful in down-grading dysplasia. 
However, residual or recurrent glands of Barrett’s epithelium are not uncommon and may not 
be an innocent finding (29,30). In our investigation ablation by APC seems more effective 
than treatment with ALA-PDT. However, in a previous study we found that in almost 80% of 
patients, treated with ALA-PDT and/or APC a complete histological response was achieved 1 
year after the first treatment (14). Sub-squamous islands of BE were more often found after 
APC (50%) than after ALA-PDT (4%). These data are supported by other groups reporting 
buried glands in 6% of patients treated with ALA-PDT (12), and 30% of patients treated with 
APC (9). Residual sub-squamous BE, which is not recognized endoscopically, may lead to 
sampling error. It could explain a negative histology directly after ablation, but presence of 
BE at the end of follow-up (cases 10 and 17). Alternatively, a true recurrence of BE can not 
be excluded, since these patients continued to have signs of reflux disease despite acid 
suppression. Another phenomenon related to sampling error is the possibility of multiple 
clonal lineages (with different histology) in BE (31). It could explain the histological pattern 
seen in patient 1, who presented with MET, but showed LGD in the first follow-up biopsy.  
To our knowledge this is the first study in which BO patients who underwent ablation therapy 
were systematically followed at the cell biological level. Biopsy samples, obtained before 
ablative therapy and at regular intervals after therapy, were assessed for proliferative capacity, 
p53 protein overexpression and ploidy status. Islands of BO may contain molecular 
abnormalities persisting despite ablative therapy. Krishnadath et al. (32) investigated archival 
material from 3 patients who had initial improvement of HGD after PDT. Biopsy specimens 
were analysed for increased proliferation, aneuploidy, p53 protein overexpression, p53 
mutations, and p16 promoter hypermethylation. These patients developed HGD after PDT, 
and one or more genetic markers were positive in all cases. In our study, we have created a 
chronological map of genetic perturbations in BO patients after both PDT and APC. After an 
initial significant down-grading of cell biological abnormalities, ie abnormal chromosome 1 
number and increased cellular proliferation, neither of the ablative methods were able to 
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remove BE completely in a subset of patients. Moreover, in these patients cell biological 
abnormalities persisted in both dysplastic and non-dysplastic Barrett’s epithelium. 
Weston et al. reported that p53 protein overexpression in Barrett’s mucosa harbouring 
LGD is a risk factor for further malignant progression (33). We found that in base line 
biopsies the extent of nuclear staining of p53 was high in HGD, whereas it was low in MET 
and LGD samples. At the end of the ablative therapy none of the five MET and one LGD 
specimens showed p53 overexpression. Only the HGD recurrence was found to have an 
increased accumulation of p53 protein, consistent with its high malignant potential. This was 
different for the proliferation index as measured by Ki67 immunostaining. At base line, 
proliferation rates were elevated in the majority of MET samples, and in all LGD and HGD 
specimens. After ablation therapy  proliferation rates continued to be elevated in most of the 
patients with  persistent  BE untill the end of follow-up. 
Aneuploidy reflects genome-wide DNA changes due to instability, which has been 
demonstrated to be a marker for malignant progression. Using flow cytometry Reid et al. (22) 
found that among patients without dysplasia or with LGD and a normal DNA content, the 5-
year incidence of cancer was 0%, whereas this was 28% in those with abnormal DNA 
content. We found previously that ploidy as measured by DNA flow cytometry correlated 
well with aneuploidy (hyperdiploidy) as measured by in situ hybridization (ISH) with a 
chromosome 1-specific centromeric DNA probe (16). This interphase DNA in situ 
hybridization technique proved to be useful for the detection of aneuploid nuclei in small foci 
of BE with or without dysplastic characteristics. Before treatment we found by means of ISH 
low percentages of aneuploid cells in MET specimens, whereas increasing percentages of 
aberrant ISH patterns were discriminated in LGD and HGD samples. This strongly suggests 
that an abnormal chromosome 1 number is an early feature in neoplastic progression. At the 
end of follow-up an abnormal chromosome 1 number was not observed in any of the available 
samples with residual or relapsing MET or LGD. Only the patient with relapsing HGD in BE 
after 36 months of follow-up had a low number of hyperdiploid cells. 
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Table 2. Histopathology,1 immunohistochemistry (IHC)2 and DNA in situ hybridization (ISH)3 data before (t=0), 1 month after ablative 
therapy (t=1), and at at the last follow-up endoscopy (t=end). 
1 NEG, no intestinal metaplasia; MET, intestinal metaplasia without dysplasia; LGD, low grade dysplasia; HGD, high grade dysplasia; NA, 
not available. 
Patient 
ID 
Histology 
at t=0 
IHC 
Ki67  
IHC 
p53  
ISH 
cen1 
Histology 
at t=1 
IHC 
Ki67  
IHC 
p53  
ISH 
cen1  
Histology 
at t=end 
IHC 
Ki67  
IHC 
p53  
ISH 
cen1  
 
1 MET 
 
NA 
 
NA 
 
NA LGD4 
 
- 
 
- 
 
+ NEG 
   
2 MET NA NA NA MET + - - MET - - - 
3 MET ++ - - MET + - - MET ++ - - 
4 MET ++ - - MET + - - NEG    
5 MET - - + NEG    NEG    
6 MET + - - MET + - - NEG    
7 MET + - - MET - - - NEG    
8 MET ++ - + MET + - NA NEG    
9 MET ++ + + MET ++ - - NEG    
10 MET + - - NEG    MET + - - 
11 MET + - - LGD4 - - - MET NA NA NA 
12 MET - - NA NEG    NEG    
13 MET + - + MET - - - NEG    
14 MET + + - MET - - + NEG    
15 MET ++ - + MET ++ - - NEG    
16 MET + - - NEG    NEG    
17 LGD + - + NEG    MET - - - 
18 LGD ++ - NA NEG    NEG    
19 LGD ++ - ++ ND5    LGD ++ - - 
20 LGD ++ - NA NEG    NEG    
21 LGD + - + MET + - - NEG    
22 HGD ++ + + HGD + ++ NA HGD + + + 
23 HGD ++ ++ NA MET - - NA NEG    
24 HGD ++ - ++ LGD ++ + - NEG    
25 HGD ++ ++ + HGD + - - NEG    
26 HGD NA NA NA NEG    NEG    
27 HGD ++ ++ ++ LGD + ++ - NEG    
28 HGD ++ ++ ++ MET - - - NEG    
29 
HGD 
++ ++ + NEG    NEG    
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2 -, +, and ++ refer for p53 IHC to ≤15%, 16-40% and >40% positive cells, for Ki67 IHC to ≤20%, 21-50% and >50% positive cells, 
respectively.  
3 -, +, and ++ refer for DNA ISH to ≤1.5%, 2-10% and >10% positive cells. 
4 Data at t=4 months; no histology at t=1. 
5 No diagnosis; insufficient material. 
 
In conclusion, we have found that after ablation therapy residual or recurrent glands of 
metaplastic epithelium can retain or accumulate cell biological abnormalities even in the 
absence of dysplasia. A long period of follow-up is therefore needed to determine the precise 
malignant potential of these molecular abnormalities for individual patients. Moreover, the 
abnormalities detected in the present study in persistent Barrett’s epithelium after ablative 
therapy have been described during the malignant progression of BO to adenocarcinoma. One 
patient in our study was indeed diagnosed with HGD after 36 months of follow-up, whereas 
other groups reported the development of adenocarcinoma under regenerated squamous 
epithelium (29,30). Endoscopic ablative treatment should therefore aim at persistent and 
complete elimination of all metaplastic cells in Barrett’s oesophagus.  
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F igure 1.  
Immunohistochemistry (IHC) for Ki67 and p53, and in situ hybridization with a chromosome 1-specific DNA probe (ISH), in Barrett’s oesophagus (BO) 
before ablative therapy (t=0) and at the last follow-up endoscopy (t=end). The IHC and ISH related signals were visualized with immuno-
peroxidase/DAB, haematoxylin was used as a counterstain (A-C, E-G, I-K, M-O, 20X objective; D, H, L, P, 40X objective). 
A-H: patient 10 (A-D, t=0; E-H, t=end). A] H&E showing intestinal metaplasia without epithelial dysplasia; B] Ki67 immunostaining revealing an 
increased proliferation zone; C] p53 IHC: an occasional positive (darker staining) cell nucleus can be seen (arrows); D] ISH: no epithelial cell nuclei 
with abnormal chromosome 1 number are present; E] H&E showing recurrent BE; F] Ki67: the proliferative compartment is again increased; G] p53 
IHC with few positive staining nuclei (arrows); H] ISH: no aneuploid cells are discriminated. 
I-P: patient 22 (I-L, t=0; M-P, t=end). I] H&E illustrating BE with HGD; J] Ki67 immunostaining revealing many positive epithelial cells; K] p53: the 
dysplastic glands are negative in one area, whereas another area is clearly positive; L] ISH revealing epithelial cell nuclei with abnormal chromosome 1 
number; M] H&E with recurrent HGD; N] Ki67 IHC displaying a dispersed pattern of proliferating cells; O] p53, again showing an alternating pattern of 
negative and positive glands; P] ISH: aneuploid nuclei are present in the dysplastic glands. 
 
 
PDT and APC effects in Barrett´s Oesophagus 
83 
0
10
20
30
40
50
60
70
80
90
100
%
aneuploidy 64 7 17
p53 31 18 17
Ki67 92 71 67
t=0 t=1 t=end
 
Figure 2.  
Bar histogram showing the percentages of cell nuclei with an abnormal chromosome 1 number (hyperploidy; black), cells with p53 protein 
overexpression (grey) and increased proliferation (white) before (t=0), 1 month after (t=1) and at the last time point (t=end) of ablative 
therapy. The aberrant ISH and IHC results (+ and ++ groups) have been combined for better visualization of cell biological alterations. 
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ABSTRACT 
 
Barrett’s esophagus (BE) is a major predisposing factor for the development of esophageal 
adenocarcinoma. Current strategies for treatment of BE, both dysplastic and nondysplastic, 
include photodynamic therapy (PDT) and argon plasma coagulation (APC). However, the 
effect of ablative therapy at the genetic level is unclear. We performed loss of heterozygosity 
(LOH) analysis of BE in baseline and follow-up biopsy specimens from 21 patients with BE 
(17 male/ 4 female) treated with PDT and/or APC. At baseline 14 patients had intestinal 
metaplasia without dysplasia (MET), 4 low-grade dysplasia (LGD) and 3 high-grade dysplasia 
(HGD). LOH was assessed using a panel of 9 polymorphic markers for evaluation of the P53 
gene on 17p, P16 on 9p, DCC and SMAD4 on 18q and the APC gene on 5q. The tissue 
specimens obtained at baseline (t=0) were analysed, as well as the first (t=1; mean interval: 4 
months) and last (t=2; mean interval: 8 months) available biopsy with residual or recurrent BE 
after ablation. At t=0 allelic loss was detected of 5q in 27%, 9p in 56%, 17p in 31% and 18q 
in 6% of informative cases. At t=1 (18 patients with persistent MET and 3 with LGD) and at 
t=2 (8 MET, 2 LGD) the LOH patterns were not statistically different from t=0. Further, 
multiple genetic lineages before and after therapy were detected in 15 cases illustrating the 
multiclonal nature of BE. We conclude that recurrent and/or persistent BE after ablative 
therapy still contains genetic alterations associated with malignant progression to cancer. 
Therefore, the goal of treatment should be the complete elimination of Barrett’s mucosa.  
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Endoscopic ablative therapies are currently used to reduce or eliminate the risk of malignant 
progression in Barrett’s esophagus (BE), a condition of the distal part of the esophagus in 
which the normal squamous epithelium is replaced by a specialized columnar type of 
epithelium, i.e., intestinal metaplasia. This metaplastic change is most likely the result of 
severe and longstanding esophageal reflux and carries an increased risk of developing 
esophageal adenocarcinoma.1-4 Esophageal adenocarcinoma is preceded by premalignant 
epithelial changes, i.e., low-grade dysplasia (LGD) and high-grade dysplasia (HGD), the latter 
being synonymous to adenocarcinoma in situ.5-7 Most commonly used ablative therapies are 
argon plasma coagulation and photodynamic therapy.8-17 However, success rates of these 
therapies vary and complete ablation is not achieved in all patients. Further, residual BE may 
be present after ablation in at least one-third of the patients and may be hidden underneath the 
restored squamous epithelial lining.  
The most common genetic events in the tumorigenesis of Barrett’s adenocarcinoma are 
abnormalities involving the P16 and P53 tumor suppressor genes, located on 9p21 and 17p13, 
respectively. Deletion is for both genes the predominant mechanism for inactivating 1 of the 2 
alleles. The remaining allele of P53 is inactivated by mutation, whereas the remaining P16 
allele is inactivated by either CpG island hypermethylation or mutation, or both.18-25 Loss of 
heterozygosity (LOH) of 9p is more prevalent than loss of 17p in metaplastic Barrett’s 
esophagus and both become more prevalent with increasing grades of dysplasia.26-27 It is 
generally believed that P16 abnormalities occur very early in tumorigenesis. Allelic loss of 
17p has also been found to be an early event and precedes the development of aneuploidy.28,29 
Moreover, 17p LOH has been found to be a predictive marker for malignant progression in 
BE.30 Other frequent genetic abnormalities in premalignant stages of BE include deletion of 
5q21, involving the APC gene, and 18q21, implicating the DCC and SMAD4 genes.31-34 Loss 
of 5q and 18q have also been reported at increasing frequencies along with successive grades 
of dysplasia in BE.27,33   
The goal of this study was to evaluate the effect of ablative therapy at the genetic level. 
Therefore, we investigated allelic imbalance at loci implicating genes involved in malignant 
progression BE, i.e. APC, P16, P53, DCC and SMAD4. The LOH profiles were determined in 
metaplastic and dysplastic BE specimens obtained before and after ablative therapy. 
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MATERIAL AND METHODS 
Patients 
Between April 2000 and August 2002, 21 patients were enrolled in our study. The mean age 
of the patients was 56 years (range 37-79 years). The following inclusion criterium was 
applied: endoscopical BE with specialized intestinal metaplasia on histological examination. 
Before ablative therapy 14 patients had metaplasia (MET), 4 patients had LGD and 3 patients 
had HGD. The mean length of the Barrett's segment was 4 cm (range 2-8 cm). Exclusion 
criteria were: (1) pregnancy, (2) acute porphyria, (3) age below 18, and (4) severe 
comorbidity. All patients were randomised and treated with APC or ALA-PDT. The treatment 
characteristics are listed in Table 1. Patients were advised to take at least 40 mg omeprazole 
daily to obtain maximal acid suppression (AstraZeneca, Zoetermeer, The Netherlands). 
Written informed consent was obtained from all patients and the study was approved by the 
Institutional Review Board of the Erasmus MC Rotterdam (MEC 178.457/1999/58). 
 
Treatment and follow-up 
Treatment was preceded by baseline endoscopy to determine the extent of the Barrett’s 
epithelium. Four-quadrant biopsy specimens for histological examination were taken at 1-cm 
intervals in patients with known HGD and at 2-cm intervals in all other patients. Patients 
receiving PDT (n=14, 67%) were pre-treated with the photosensitizer 5-ALA (Sigma-Aldrich 
Chemie BV, Zevenaar, The Netherlands) 60 mg/kg orally, 4 hours before application of light 
with a wavelength of 630 nm with a KTP/532 dye laser module (Laser scope, San Jose, 
California, USA). Light was administered via an endoscopically placed balloon (Wizzard X-
cell, Wilson-Cook Medical Inc, Winston salem, North Carolina, USA). A dose of 1x100 J/cm2 
was given. Residual BE was treated by APC. For APC an Argon Beamer 2 device was used 
with a coagulation power setting of 65W and an argon gas flow rate of 2.0 l/min (Erbe 
Medizintechnik, Tűbingen, Germany). Patients receiving APC alone (n=7, 33%) were initially 
treated in 2 sessions, with a 1-month interval between sessions. If macroscopic BE was 
observed after 2 sessions, additional APC was performed until all visible BE was cleared. 
The therapeutic effect was evaluated endoscopically and histologically after 1 month, then at 
3-months intervals, and after 1 year at 6-months intervals. Sampling was performed at 1 cm 
intervals with 4-quadrant biopsies from the treated area and from any residual macroscopic 
focus of BE present. Methylene blue staining was used to better identify residual BE. An extra 
specimen in the cardiac region of the stomach was obtained to serve as a control for 
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immunohistochemical and cytogenetic analysis. All biopsies were formalin-fixed and 
paraffin-embedded, and stained with hematoxylin & eosin (H&E). Using standard criteria all 
histological diagnoses were made by an experienced gastro-intestinal pathologist (HvD). 
 
Tissue microdissection, PCR, and LOH analysis 
Laser capture microdissection and LOH analysis of predefined metaplastic and dysplastic 
areas was performed on a Pixcell II (Arcturus, Mountain View, CA) as described before by 
us.35 Gastric cardia biopsies served as normal tissues and were subjected to similar 
experimental conditions. Before microdissecting, 4 µm formalin-fixed, paraffin-embedded 
sections were deparaffinized using standard methods, stained for 10 sec with H&E, and 
subsequently dehydrated and air dried. The membrane containing the isolated cells of interest 
was carefully peeled from the cap and submerged for at least 2 days at 55°C in 50 µl of DNA 
isolation buffer containing 10 mM Tris-HCl (pH 8.0), 1 mM of EDTA, 1% Tween 20, and 0.1 
mg/ml proteinase K. Proteinase K was inactivated by incubation at 95°C for 8 min. 
LOH analysis was performed with a set of 9 polymorphic markers for evaluation of the APC 
gene on 5q (D5S346), P16 on 9p (D9S1870, D9S1748, D9S274 and D9S269), the P53 gene 
on 17p (D17S786, TP53), and DCC and SMAD4 genes on 18q (D18S484 and D18S1110). 
The polymorphic markers were selected from the National Center for Biotechnology 
Information (http://www/ncbi.nlm.nih.gov/genemap/) and Genome Data Base databanks 
(http://gdbwww.gdb.org/) based on heterozygosity frequency, as well as coverage and 
flanking the region of interest. The location of the primers was determined by the most recent 
draft sequence (http://genome.ucsc.edu/). The PCR reaction mixture (15 µl) contained 1.5 µl 
10x amplitaq gold buffer, 2.5 mM of MgCl2, 0.2 mM of deoxynucleotide triphosphate, 0.9 
units of AmpliTaq Gold (Perkin-Elmer, Wellesley, MA), 1µl of DNA, 0.05 µCi α[32P]dATP, 
and 30 ng forward and 30 ng reverse primer. Five-minute denaturation at 95°C was followed 
by 35 cycles of 30 s at 95°C, 45 s at the appropriate annealing temperature (Table 1), and 45 s 
at 72°C. Elongation was achieved by 10 min at 72°C followed by chilling to 4°C. The PCR 
products were mixed with 13 µl of loading buffer (95% formamide, 20 mM EDTA, 0.05% 
bromphenol blue and 0.05% xylene cyanol), denatured for 5 min at 95°C, and kept on ice. 
Then 4 µl of the PCR product was loaded on a denaturing 6% polyacrylamide gel containing 
7 M urea and run at 65 W for 1.5–2 h. Gels were dried and radiographed. Autoradiograms 
were evaluated by visual inspection. Allelic imbalance was defined as near or complete loss of 
a band in the tumour relative to the corresponding normal sample. Allelic conservation was 
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defined as the clear presence of both alleles in both abnormal and corresponding normal 
DNA. All of the other situations were judged as non-informative. 
 
Statistics 
The χ2 test was applied for comparisons of the LOH results. p=0.05 (2-tailed) was taken as the 
limit of significance. 
  
Table 1. Patient characteristics. 
Patient 
ID 
Age at intake 
(years) 
Sex Base line 
histology1 
End point 
histology1 
Length of BE segment 
(cm) 
Therapy Follow-up 
(months) 
1 53 F MET NEG 5 PDT 9 
2 53 M MET MET 5 PDT 18 
3 67 M MET NEG 4 PDT 30 
4 37 M MET NEG 2 APC 12 
5 63 M MET MET 3 PDT 12 
6 45 M MET NEG 4 PDT 30 
7 44 M MET NEG 3 PDT 24 
8 55 M MET NEG 5 PDT 24 
9 55 M MET NEG 3 APC 24 
10 58 M MET MET 3 PDT 24 
11 51 M MET NEG 4 PDT 24 
12 39 F MET MET 4 APC 6 
13 49 M MET NEG 5 PDT 30 
14 51 M MET NEG 4 PDT 18 
15 66 M LGD LGD 4 PDT 24 
16 51 F LGD NEG 4 APC 12 
17 59 M LGD NEG 5 APC 18 
18 48 M LGD NEG 4 APC 24 
19 74 M HGD NEG 3 PDT 30 
20 74 F HGD NEG 8 APC 24 
21 79 M HGD NEG 3 PDT 9 
 
NEG, no metaplasia or dysplasia; MET, intestinal metaplasia without dysplasia; LGD, low 
grade dysplasia; HGD, high grade dysplasia. 
Genetic effects of PDT and APC in Barrett’s esophagus 
95 
RESULTS 
Loss of heterozygosity (LOH) analysis of BE was performed in baseline and follow-up biopsy 
specimens from 21 patients with BE (17 male/ 4 female, mean age 56 years, mean length of 
BE 4 cm) treated with PDT or APC (Table 1). At baseline, 14 patients had intestinal 
metaplasia without dysplasia (MET), 4 low-grade dysplasia (LGD) and 3 patients high-grade 
dysplasia (HGD). Biopsy samples were obtained at regular intervals (mean follow-up: 20 
months, range 6-30). From these 21 patients, 80 microdissected metaplastic and dysplastic 
tissue specimens were available for genetic evaluation, as well as 21 gastric cardia controls. 
LOH was assessed using a panel of 9 polymorphic markers for evaluation of the P53 gene on 
17p (D17S786, TP53), P16 on 9p (D9S1870, D9S1748, D9S274 and D9S269), DCC and 
SMAD4 on 18q (D18S484 and D18S1110) and the APC gene on 5q (D5S346). For all samples 
(and markers) combined the percentage of informative cases was 67% for 5q, 81% for 9p, 
79% for 17p and 92% for 18q. In a time-course study, we initially analysed tissue specimens 
obtained at baseline (t=0), as well as the first (t=1) and last (t=2) available sample with 
residual or recurrent BE after ablation. In 5 patients, BE remained present in the last follow-up 
biopsy, whereas in the remaining 16 patients no BE was found endoscopically and 
histologically (Table 1). However, in 12 of the 21 patients (57%) an alternating pattern of 
absence and presence of BE was detected in the follow-up biopsies, irrespective of their 
histological status at the end point. We found no significant differences between patients 
initially treated with PDT or APC. For the investigated time points at t=1 and t=2 the highest 
grade of dysplasia was used, or, if there were more samples available with the highest grade, 
the specimen with most genetic alterations was selected. Examples of LOH are depicted in 
Figure 1, whereas a summary of the results is listed in Table 2. 
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Before therapy allelic imbalance for MET was 10% on 5q, 70% on 9p, 10% on 17p and  0% 
on 18q; for LGD 50% on 5q, 33% on 9p, 33% on 17p and 0 on 18q; for HGD 67% on 5q, 
33% on 9p, 100% on 17p and 33% on 18q (informative cases; Figure 2A). Along with 
increasing degree of dysplasia a significant increase was found of alteration of 17p (p= 0.01), 
whereas a statistical trend was observed for loss of 18q (p= 0.07). For all BE samples 
combined LOH at t=0 was detected of 5q in 27%, 9p in 56%, 17p in 31% and 18q in 6% of 
informative cases. At t=1 18 MET and 3 LGD samples were available for analysis, obtained 
at a mean interval of 4 months after ablation (range 1-18 months). LOH for MET was 0% on 
5q, 36% on 9p, 14% on 17p and 18% on 18q; for LGD 0% on 5q, 67% on 9p, 50% on 17p 
and 33% on 18q (informative cases). LOH was found for all BE samples combined at t=1 of 
5q in 0%, 9p in 35%, 17p in 24% and 18q in 20% of informative cases. Ten patients (8 MET, 
2 LGD) were available for evaluation at t=2, obtained at a mean interval of 8 months after 
ablation (range 4-24 months). Allelic loss for MET was 0% on 5q, 57% on 9p, 29% on 17p 
and 25% on 18q; for LGD 0% on 5q, 100% on 9p, 50% on 17p and 0% on 18q (informative 
cases). LOH was discriminated for all BE specimens combined at t=2 of 5q in 0%, 9p in 56%, 
17p in 44% and 18q in 20% of informative cases. The LOH patterns of the BE’s at t=0 (14 
MET, 4 LGD, 3 HGD), t=1 (18 MET, 3 LGD) and t=2 (8 MET, 2 LGD) were not statistically 
different (Fig. 2b), despite histological downgrading of dysplasia after therapy. In addition, in 
all 80 BE samples analyzed we observed more than one genetic lineage before ablative 
treatment in 1 HGD, 2 LGD and 3 MET patients. Different genetic lineages before and after 
therapy were detected in 15 cases illustrating the multiclonal nature of BE (Fig. 3).   
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FIGURE 1. 
Examples of allelic imbalance of the used polymorphic markers (arrowheads). Above every panel the 
polymorphic marker name is given, whereas below the panel the corresponding tissue is shown: MET, LGD, and 
N (normal gastric cardia). Marker-patient data: D5S346, pat. 3, t=0; D9S1870, pat. 6, t=1; D9S1748, pat. 11, 
t=0; D9S274, pat. 4, t=0; D9S269, pat. 6, t=1; D17S786, pat. 20, t=0; TP53, pat. 15, t=2; D18S484, pat. 6, t=1; 
D18S1110, pat. 21, t=0. 
 
 
 
 
 
FIGURE 2A.  
Bar histograms showing the percentages of loss on 5q, 9p, 17p and 18q in the BE samples before treatment. 
Going from MET to LGD and HGD a significant increase was found in the number of 17p alterations, whereas a 
statistical  trend was observed for loss on 18q. 
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FIGURE 2B.  
Bar histograms depicting the percentages of loss on 5q, 9p, 17p and 18q in the BE specimens (MET/LGD/HGD 
combined; see Table 2) before (t=0) and after ablative therapy. T=1 reflects the first available BE samples, t=2 
denotes the last available BE tissues after ablation. There are no statistical changes in the LOH patterns at base 
line and during follow-up indicating that genetic abnormalities were still present after treatment. 
FIGURE 3.  
Schematic representation illustrating the presence of multiple genetic lineages in BE before and after ablative 
therapy. The definition of the genetic lineages was based on differential patterns of allelic loss (maternal or 
paternal) of all 9 polymorphic markers used in the study.  In patient 15 two LGD clones were found before 
ablation, a third was seen at the first follow-up at 6 months, whereas all three lineages were again detected at the 
last available follow-up. Patient 20 was found to have an LGD and HGD lineage before therapy, a third Barrett 
clone was revealed during follow-up at 2, 6 and 11 months after ablation. 
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DISCUSSION 
Barrett’s esophagus is believed to be associated with an increased risk of developing 
esophageal adenocarcinoma.36 Although the latter is clear for patients with HGD, patients 
with MET and LGD also appear to have an increased risk.4 We investigated 80 samples of BE 
before and after ablation by ALA-PDT or APC for LOH at tumor suppressor loci known to be 
involved in malignant progression in BE, i.e. the APC gene on 5q, P16 on 9p, the P53 gene on 
17p, and DCC and SMAD4 on 18q. Before treatment frequency patterns of loss were observed 
that were in agreement with previously published reports, e.g. frequent LOH at the P16 locus 
starting already in metaplasia without dysplasia.19,24,25,28,29,33,37 In our time course study the 
profiles of imbalance at 5q, 9p, 17p and 18q for the whole group of BE patients were not 
statistically different before and after ablative therapy, despite absence of HGD at t=1 and 
t=2. This is suggestive of a certain selection after ablation of BE clones with a more 
“progressive” genotype. However, more cases are needed to determine, whether there is an 
association between histological downgrading and a specific genetic signature. 
It has been described that multiple clones with different genetic makeup can be present in 
BE.38 Galipeau et al.39 found a mosaic of clones in premalignant Barrett’s tissue with 
differential expansion of some clones throughout the Barrrett’s segment. These findings 
indicate a complex pattern of neoplastic evolution rather than a simple pathway. Recently, the 
same group reported that the combination of genetic instability and clonal expansion are 
better predictors of malignant progression than either alone.40 In the 80 BE samples more than 
1 genetic lineage before ablative treatment was detected in 6 patients. Moreover, different 
genetic lineages before and after therapy were detected in more than two thirds of cases 
confirming the profound multiclonal nature of BE. This could have implications with respect 
to selection of “progressive” clones during treatment, which is suggested by our data (see 
above). This also could explain an alternating pattern of absence and presence of BE during 
therapy, as specific clones of BE might be able to progress from a submicroscopic hidden 
state to macroscopic and histological detection. 
It has been speculated that ablative therapies could reduce or even eliminate malignant 
progression.41 Ablative therapies have been shown to successfully downgrade dysplasia, 
however, residual or recurrent glands of Barrett’s epithelium are not uncommon and may 
confer the chance of malignant degeneration.42,43 In our series ablation by APC seems slightly 
more effective than treatment with ALA-PDT. However, in a previous study we found that in 
almost 80% of patients, treated with ALA-PDT and/or APC a complete histological response 
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was achieved 1 year after the first treatment.17 Sub-squamous islands of BE were more often 
found after APC (50%) than after ALA-PDT (4%). These data are supported by other studies 
describing buried glands in 6% of patients treated with ALA-PDT, and 30% of patients 
treated with APC.12,14 Residual sub-squamous BE, which is not recognized endoscopically, 
may lead to sampling error. It could explain alternating patterns of absence and presence of 
BE after treatment, which was observed in about half of our patients. The alternating patterns 
also suggest that it is not realistic to assume that treated patients currently without BE will 
remain free of intestinal metaplasia in the future. 
To our knowledge this is the first study in which BE patients who had undergone ablation 
therapy were systematically screened for allelic imbalance at tumor suppressor loci involved 
in the development of Barrett’s adenocarcinoma. Krishnadath et al.44 investigated archival 
material from 3 patients who had initial improvement of HGD after PDT. Biopsy specimens 
were analysed for increased proliferation, aneuploidy, p53 protein overexpression, p53 
mutations, and p16 promoter hypermethylation. These patients developed HGD after PDT, 
and in all cases one or more markers were positive. In a previous study we investigated 
cellular proliferation, aneuploidy, and p53 protein overexpression in BE patients after PDT 
and APC treatment.45 After an initial downgrading of cell biological abnormalities, i.e., 
aneuploidy and increased cellular proliferation, both ablative methods were not able to 
remove BE completely in a subset of patients. In these patients biological abnormalities 
persisted in both dysplastic and non-dysplastic Barrett’s epithelium. 
In conclusion, we have characterized Barrett’s tissue before and after ablation by LOH and 
observed that genetic alterations could sustain or arise after ablative therapy. Importantly, 
these genomic aberrations appear to be situated at tumor suppressor loci known to be involved 
in malignant progression in BE. This strongly suggests that ablative therapy, although being a 
safe technique, might not be effective in the long-term. The frequent detection of sub-
squamous BE, and even adenocarcinomas reported underneath completely restored squamous 
mucosa, is not in contradiction with our findings.42,43 This indicates that long-term follow-up 
is warranted after ablation with PDT or APC. Therefore, the primary goal of ablative therapy 
should be complete elimination of all Barrett´s mucosa. 
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The importance of an in-depth understanding of Barrett’s oesophagus, (BO) a major risk 
factor for oesophageal adenocarcinoma, is ultimately to decrease the morbidity and mortality 
from this malignancy by the early detection of the precursor lesion dysplasia and the search 
for an appropiate therapy. Although the risk of malignant progression is found to be 30- 50x 
greater in patients with BO compared to the general population and estimated to be 
approximately 0.5% per year (1), we still do not know exactly what the natural progression is 
from BO without dysplasia, to low-grade dysplasia (LGD), high-grade dysplasia (HGD) and, 
finally, cancer. In addition, it is largely unknown  what the risk factors for neoplastic 
progression are. 
 
Natural progression of Barrett´s oesophagus and risk factors for neoplastic progression 
In the first part of this thesis, the results of a retrospective survey of a cohort of 105 patients 
with long-segment Barrett’s oesophagus (58 males and 47 females; mean age 63.4 years; 
mean length of BO-segment 7.1 cm), established between 1973 and 1984 in the Erasmus MC, 
are described to establish the risk of malignant progression in patients with BO who had  not 
been offerend  endoscopic surveillance. In addition, a risk factor analysis for neoplastic 
progression was performed. For this, particularly  patient factors present at index-endoscopy, 
such as age, gender, ulcera within the Barret’s mucosa and length of the Barrett’s segment 
were considered. 
This cohort was previously studied in 1996 (2). However, we tried to find more accurate data 
on cancer incidence by redefining the cohort by applying current guidelines on the diagnosis 
of BO. For this, the histological presence of intestinal metasplasia and the macroscopic 
presence of  BO is required. 
 
The major conclusions that we could draw from the first part of this thesis were the following: 
 
• The annual risk of developing HGD or adenocarcinoma in patients with long-segment 
(≥ 3 cm) BO is low, i.e., 0.83%, meaning the occurrence of one cancer case per 221 
patient-years (0.45%) of follow-up and one HGD case per 266 patient-years (0.38%) 
of follow-up with a mean follow-up of the cohort of 12.7 years. 
• Death due to adenocarcinoma is, even in a cohort of patients with long-segment BO, 
relatively uncommon, i.e. 6/72 (4%). 
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Secondary conclusions that we could draw from this study were: 
• A longer length of BO is associated with an increased risk of progression to HGD or 
cancer. 
• The presence of an ulcer in BO at index-endoscopy confers to an increased risk of 
progression  of HGD and cancer. 
• Ulcera in BO are more commonly found in longer segments of BO.  
 
The total of 6 cancers in 1329 patient-years (1 case per 221 patients-years) in the redefined 
cohort was not markedly different from the cancer risk of 1 in 180 patient-years found in our 
previous study and is comparable with those in recently published prospespective studies, 
reporting one case of cancer per 187 to 208 patient-years of follow-up (3,4) . Five of 11 
patients with HGD or cancer in BO had a potentially curative treatment. One of these patients, 
however, died 3 months after surgery, of postoperative complications, whereas another patient 
died unexpectedly 4 years after surgery of liver metastases presumably of oesophageal origin. 
The remaining 6 patients were considered unfit for surgery because of advanced age or severe 
comorbidity (n = 5), or refused surgery (n = 1). Overall, in our cohort, 4/72 (6%) deaths at the 
end of follow-up were related to complications of surgical treatment of esophageal 
adenocarcinoma (n = 1) or metastatic disease (n = 3) after initial HGD or adenocarcinoma in 
BO.  
 In a study from Scotland, MacDonald et al. (5) reported equally disappointing 
findings. Of 409 patients with BO, only 143 (35%) were considered suitable for surveillance. 
Five (3.5%) of these  patients developed oesophageal carcinoma; only one had been detected 
during surveillance. This  patient died however as result of postoperative complications. 
 Presently, endoscopic surveillance is recommended for all patients with BO to detect 
early-stage neoplastic changes (6). This was recently supported by findings from three 
retrospective studies of patients with adenocarcinoma of the oesophagus and gastric cardia, in 
which a survival benefit was found for the 4–18% of patients who had an upper 
gastrointestinal endoscopy some time before a cancer diagnosis was made (7-9). In contrast, 
the results of our study show that both cancer incidence and mortality from it are low in 
patients with BO. Therefore, the benefits of surveillance in terms of life-years gained may be 
relatively small compared to the costs and resources involved. 
 Currently available, low-risk, non-invasive, endoscopic ablative techniques, which aim 
to reverse BO to squamous epithelium in an anacid environment, might be a promising 
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alternative therapy for patients with nondysplastic as well as dysplastic BO and, if effective, 
may therefore reduce the need for costly surveillance programs.  
 
Efficacy of argon plasma coagulation and photodynamic therapy for the removal of 
Barrett´s oesophagus 
In the second part of this thesis the clinicopathologic efficacy of two of the most widely 
perfomed endocopic ablation prcedures, is reported. We were the first to compare argon 
plasma coagulation (APC), which is a thermal method and 5 aminolevulinic acid induced 
photodynamic therapy (ALA-PDT), which is a photo-chemical method, in a prospective 
randomized trial. In this trial, 40 patients with BO without dysplasia or with LGD were 
randomized to treatment with ALA-PDT as a single dose of 100 J/cm2 (n=13), ALA-PDT as 
a fractionated dose of 20 and 100 J/cm2 (n=13) and APC 65W in two sessions (n=14).  
Before this study started, it was already known that endoscopic ablation therapy could result 
in macroscopic reduction of the size of the Barrett’s segment and that histologic downgrading 
of dysplasia could be established with these techniques. However, complete elimination of 
BO only rarely occurred, despite adequate acid suppression with medical or surgical anti-
reflux measures. Therefore, this research was taken further and not only the effect of these 
therapeutic modalities was studied on the macroscopic level, but also on the miscrocopic 
level, i.e., it was investigated how often residual or recurrent foci of Barrett’s tissue were 
found after ablative therpy, and  whether  these foci were  located next to or within the treated 
segment or underneath the (neo)squamous mucosa.  
Besides, in additional studies, the malignant potential of these persisting foci of BO was 
investigated with Ki-67 and  p53 immunohistochemistry, and DNA in situ hybridisation  with 
a chromosome 1 specific probe. Using these techniques, proliferative capacity, p53 gene 
abnormalities and ploidy status were  assessed, as these are known to be associated with 
neoplastic progression. Moreover,  loss of heterozygosity (LOH) analysis was performed for 
the most common tumor suppressor genes that are involved in the carcinogenesis of BO, i.e., 
p53 on 17p, p16 on 9p, APC on 5q and DCC/SMAD4 on 18q using a panel of 9 polymorphic 
markers. This last study was performed in a group (n=21) of BO patients without 
dysplasia(n=14), with LGD(n=4), and with HGD (n=3) prior and following  ablative therapy. 
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Conclusions we could draw from the second part of this thesis were the following: 
 
• Single treatment with APC and ALA-PDT reduces the total surface of BO 
significantly . 
• A fractionated dose of 20 and 100J ALA-PDT causes more pronounced regression of 
BO compared to a single dose of 100J ALA-PDT, both macroscopically and 
microscopically. 
• Single treatment with APC or ALA-PDT rarely results in complete elimination of BO; 
complete reversal is seen in only 5/25 (20%) of patients treated with ALA-PDT alone 
and in 5/14 (36%) patients treated with APC alone. 
• Subsequent treatment sessions with APC in patients with persisting BO after APC and 
ALA-PDT, results in complete reversal of BO in at least two thirds of patients when 
administred with a maximum of 2  treatment sessions (67% versus 86%, respectively). 
• BO after treatment is predominatly found next to (neo)squamous epithelium in both 
fractionated and single dose ALA-PDT. Subsquamous islands of BO are more often 
found after APC (50%) than after ALA-PDT (4%). 
• Both APC and ALA-PDT are relatively safe techniques; severe chest pain and 
(transient) elevated liver enzyme levels are the most important side-effects of ALA-
PDT. Nausea and vomiting are more common in patients treated with ALA-PDT 
compared with APC. 
• Single treatment with (fractionated) ALA-PDT and APC achieves a significant 
downgrading of  aneuploidy and abberant proliferation, but not  p53 overexpression. 
• Despite intensive ablative therapy with subsequent sessions of APC, metaplastic cells 
with cell-biological and genetic alterations are still present in both dysplastic and non-
dysplastic persistent BO. 
 
Up to now, most groups have focussed on just one of these two (or other) ablative therapy 
modalities. As stated previously, our group was the first to compare in a randomized trial two 
ablative modalities. The end-point of the study were endoscopic reduction of the BO surface 
and the microscopic presence or absence of Barrett’s epithelium at different time points (at 6 
weeks, 6, 12, 18 and 24 months). At 6 weeks there was no significant difference between   
ALA-PDT and APC , with a complete histologic response rate of 33% and 36% for the ALA-
PDT fractionated dose and APC, respectively. After12 months, residual BO was found in only 
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10% of the ALA-PDT group and in 33% of the APC-group. This difference was however not 
significant, probably because of the relatively small number of patients that had been 
enrolled. Subsquamous BO was more commonly seen after APC (50%) than after PDT(4%). 
These results are in keeping with previous studies reporting buried glands in 6% of patients 
treated with ALA-PDT  (10) and 30% of patients treated with APC (11). 
 More recently another randomised study comparing APC and 5-ALA PDT in patients 
with only nondysplastic BO reported similar results (12). Complete macroscopic reversal of 
BO was achieved in 17/34 (50%) of patients of the PDT group and in 33/34 (97%) of  the 
APC-group after a median number of respectively 2 and 3 treatment sessions. Buried glands 
were found in 24% of  patients treated with PDT and 21% of the patients treated with APC 
with a median follow-up of 12 months.  
 Until now, one randomised trial compared two thermal methods, i.e., multipolar 
electrocoagulation (MPEC) and APC (13). It was assumed by the authors of this study that, 
although there were no statistically significant differences between MPEC and APC,  MPEC 
required numerically fewer treatment sessions, and endoscopic and histologic ablation was 
achieved in a greater proportion of patients compared with treatment with pantoprazole and 
APC.  
All studies have reported that squamous re-epitheliasation after ablation therapy only 
occurs in the presence of adequate acid suppression. However, in neither of the studies 
complete elimination of BO was established irrespective of what ablation procedure was 
applied (10-24). The histopathological findings after treatment were the same for all ablation 
techniques, irrespective of whether a thermal or a nonthermal method was used. Although 
endocopic reduction of the surface of BO was substantial and histologic downgrading of 
dysplasia can be established, almost all studies have reported that (subsquamous) islands of 
BO are present after ablation. The above-mentioned study by  Dulai and collegues (5)  
showed that serial sectioning of the tissue blocks, in which  subsquamous located specialised 
intestinal epithelium was identified,  an extension to the surface was present in all cases. This 
suggests that it  is irrelevant to distinguish microscopic foci of residual BO from subsquamous 
foci of BO. These authors suggest that future studies should not only focus on the presence or 
absence of BO   but also concentrate on the malignant potential of persisting foci of BO.  
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Malignant potential  of residual foci of Barrett´s epitheliuim after ablation therapy 
In this thesis it is reported that despite extensive ablation therapy, islands of BO with 
cellbiological and genetic abnormalities persist even after a significant downgrading of cell 
biological abnormalities, i.e.,  aneuploidy and increased cellular proliferation. Moreover, 
these abnormalities were found in the absence of dysplasia. Aneuploidy reflects genome-wide 
DNA changes due to instability, which has been demonstrated to be a marker for malignant 
progression. Using flow cytometry, Reid et al. (25) found that among patients without 
dysplasia or with LGD and a normal DNA content, the 5-year incidence of cancer was 0%, 
whereas this was 28% in those with abnormal DNA content. Previously, we found that flow 
cytometry, the most commonly used technique for measuring abnormal DNA content, 
correlated well with  ploidy changes   as measured by in situ hybridisation (ISH) with a 
chromosome -1 specific  DNA probe (26). This interphase   technique proved very useful for 
the detection of aneuploid cells in small foci of BO. By means of ISH, we found a low 
percentage of aneuploid cells in BO samples without dysplasia, whereas increasing 
percentages of abberant ISH patterns were identified in LGD and HGD samples. This strongly 
suggests that aneuploidy is an early feature in neoplastic progression.  
Overexpression of p53 protein  has   been found with increasing frequency in BO without 
dysplasia, LGD, HGD and finally adenocarcinoma. Weston et al.(27) reported that p53 
overexpression in Barrett’s mucosa harbouring LGD was a risk factor for further malignant 
progression. We found that in baseline biopsies the extent of nuclear staining was high in 
HGD, whereas it was low in BO without dysplasia and LGD samples. At the end of follow-
up, only  recurrent HGD  was found to be associated with an increased accumulation of p53 
protein, which is consistent with the high malignant potential of HGD. One must however 
keep in mind that immunohistochemical p53 accumulation may occur without mutations in 
the gene, and,  conversely, also mutations without p53 accumulation have been reported. 
 We found by LOH analysis, in baseline biopsies, patterns of loss that were in 
agreement with previously published reports (28-35), detecting frequent LOH at the p16 locus  
already in  BO without dysplasia. In our time course study, the profiles of imbalance at 5q, 
9p, 17p and 18q for the whole group of BE patients were not statistically different before and 
after ablative therapy, despite the absence of HGD after ablation. This is suggestive of a 
certain selection   of BE clones with a more “progressive” genotype by ablative techniques. In 
the 80 investigated BE samples, more than 1 genetic lineage before ablative treatment was 
detected in 6 patients. Moreover, different genetic lineages before and after therapy were 
detected in more than two thirds of cases confirming the profound multiclonal nature of BE. 
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Krishnadath and collegues (36) also studied proliferation indices, aneuplody, p16 and p53 
expression and described persisting genetic abnormalities, even when there was apparent 
initial histologic improvement. They reported however on only 3 patients with initial 
improvement of dysplasia after PDT who, in the course of time, had again evidence of high-
grade dysplasia. More  research is needed to establish a significant association between 
histological downgrading and a specific genetic signature. 
    
Concluding remarks 
Better risk stratification of patients with BO is  necessary. The search for (a panel of ) 
biomarkers that could predict which patients are at increased risk for progression must be 
continued. At this moment, we should aim at complete elimination of all Barrett’s mucosa. 
Improvement of currently available techniques and the development of new ablative 
techniques might contribute to this aim. Two of the most promising modalities include the use 
of liquid nitrogen spray and high-intensity focused ultrasonic energy (37,38). New 
technologies in surveillance, like narrow-band imaging and spectroscope techniques (39) 
could help to distinguish dysplastic from nondysplastic areas within the Barrett’s segment and 
could provide an adjunct to histopathology reports in order to overcome the interobserver 
variablity and help to stratify patients for the several available endoscopic ablation therapies 
or surgery. However, we know that the large majority of patients with BO go unrecognized 
and present unfortunately with late stage disease. 
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Barrett’s oesophagus is a condition in which, due to chronic gastro-oesophageal reflux, the 
normal squamous lining is transformed into a specialized columnar epithelium with goblet 
cells (intestinal metaplasia). This metaplastic epithelium has been recognized as major risk 
factor for developing cancer. Compared to the general population, patients with BO have a 
30-50 fold increased risk for developing oesophageal adenocarcinoma. 
During the past decades there has been an alarming rise in the incidence of oesophageal 
adenocarcinoma. The prevalence is highest in white middle-aged males of higher socio-
economic classes. However, exact data on cancer risk in patients with long-segment Barrett’s 
oesophagus (BO) from older studies are often difficult to interpret, since the definition of BO 
which has an endoscopic red velvety appearance, has evolved from an endoscopic (>3cm 
mucosal changes) to a histological diagnosis, requiring the presence of intestinal metaplasia. 
Moreover, currently BO is also diagnosed in patients with short-segment (<3 cm) mucosal 
changes. 
  
In the work, described in CHAPTER 2, the diagnoses in the Rotterdam BO cohort was 
redefined on current standards to obtain more accurate data on cancer risk in patients who had 
not undergone standard endoscopic surveillance. In addition, it was determined which patient 
factors present at index endoscopy were associated with neoplastic progression in BO. The 
Rotterdam BO cohort comprises all patients with ≥ 3 cm BO, diagnosed at endoscopy 
between 1973 and 1984. In the present study, only patients with intestinal metaplasia were 
included (n = 105). Follow-up data were obtained by questionnaires and/or interviews with 
patients or treating physicians. A Kaplan-Meier analysis was used to estimate 20-year risks. 
The mean length of the BO was 7.1 cm (range: 3–15 cm). Cancer in BO developed in 6/105 
(6%) patients, and high-grade dysplasia (HGD) in 5/105 (5%) patients during 1329 patient-
years of follow-up, which equals one cancer case per 221 patient-years and one HGD case per 
266 patient-years. After a mean follow-up of 12.7 years, 72 (69%) patients had died; only 4 of 
them died of oesophageal cancer or its treatment. A longer length of BO was associated with 
an increased risk of progression to HGD or cancer (P =0.02). Six of 24 patients who ever had 
low-grade dysplasia progressed to HGD or cancer 2–16 years after a diagnosis of BO. We 
concluded that he annual risk of developing HGD or adenocarcinoma in patients with long-
segment BO is low, i.e.0.83%, and that death due to adenocarcinoma is, however, uncommon, 
even in a cohort of patients with long-segment BO. 
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Since Barrett’s oesophagus is a major risk factor for developing oesophageal adenocarcinoma, 
most centres have implemented endosocopic biopsy surveillance programs to detect precursor 
stages of adenocarcinoma (i.e. low grade dysplasia (LGD) and high grade dysplasia (HGD)). 
There is much interest in non-invasive, low-risk, ablative techniques that can eliminate 
precursor stages or early invasive cancer, since oesophagectomy, mostly performed once 
HGD or invasive cancer has developed, confers a high mortality and morbidity.  
The most commonly used techniques are thermal destruction by argon plasma coagulation 
(APC) and photochemical destruction by photodynamic therapy (PDT).  Photochemical 
ablation using PDT is based on an intracellular accumulation of the photosensitizer 
protoporphyrin IX (PpIX) in tissue. There are different photosensitizers. The most common 
used are an enriched form of hematoporphyrin (Photophrin) and 5-aminolevulinic acid 
(ALA). ALA is a precursor molecule in the heme biosynthetic pathway that induces an 
endogenous production of PpIX. Photophrin is given to patients intravenously, whereas ALA 
is administered orally. PpIX is activated by photo-irradiation using laser light with an 
appropriate wavelength. This generates singlet oxygen production resulting in tissue 
destruction. APC employs a cautery probe that transfers electrical energy through ionized, 
electro conductive plasma of argon gas to the tissue surface, again resulting in tissue 
destruction. 
The majority of studies using ablation using APC and PDT have focused on dysplasia and 
early cancer with a success removal rate of up to 80%. For patients with metaplasia without 
dysplasia, APC has been the most popular technique with a success rate in up to 98% 
(CHAPTER 1). 
  
We performed a randomised trial to compare 5-aminolevulinic acid induced PDT and with 
APC with respect to complete reversal of BO (CHAPTER 3). 
Patients with BO (32 no dysplasia and eight low grade dysplasia) were randomised to one of 
three treatments: (a) ALA-PDT as a single dose of 100J/cm2 at four hours (PDT100; n=13), 
(b) ALA-PDT as a fractionated dose of 20 and 100J/cm2 at one and four hours, respectively 
(PDT20+100; n=13) or (c) APC at a power setting of 65W in two sessions (APC; n=14). If 
complete elimination of BO was not achieved by the designated treatment, the remaining BO 
was treated by a maximum of two sessions of APC. 
We found that mean endoscopic reduction of BO at six weeks was 51% (range 20-100) in the 
PDT100-group, 86% (range 0-100%) in the PDT20+100-group, and 93% (range 40-100%) in 
the APC-group (PDT100 v PDT20+100, p<0.005; PDT100 v APC, p<0.005; and PDT20+100 
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v APC, NS) with histological complete ablation in 1/13 (8%) patients in the PDT100-group, 
4/12 (33%) in the PDT20+100-group, and 5/14 (36%) in the APC-group (NS). Remaining BO 
was additionally treated with APC in 23/40 (58%) patients. Histological examination at 12 
months revealed complete ablation in 9/11 (82%) patients in the PDT100-group, in 9/10 
patients in the PDT20+100-group, and in 8/12 (67%) patients in the APC-group (NS). At 12 
months, no dysplasia was detected. Side effects, that is, pain (p<0.01), and nausea and 
vomiting (p<0.05), and elevated liver transaminases (p<0.01) were more common after PDT 
than APC therapy. One patient died three days after treatment with PDT, presumably from 
cardiac arrhythmia.  
This study shows that APC alone or ALA-PDT, in combination with APC, can lead to 
complete reversal of Barrett’s oesophagus in at least two thirds of patients when administered 
in multiple treatment sessions. As the goal of treatment should be complete reversal to 
Barrett’s epithelium, we do not recommend these techniques for the prophylactic ablation of 
BO. 
 
The study, described in CHAPTER 4, examined the effect of ablative therapy on Barrett’s 
oesophagus at cell cycle and genetic levels. The premalignant potential of residual or 
recurring Barrett’s epithelium was assessed by p53 immunohistochemistry, Ki67-related 
proliferative capacity, and DNA ploidy status (i.e. an abnormal chromosome 1 number) as 
measured by interphase in situ hybridization.  
Twenty-nine patients with Barrett’s oesophagus (23 male and 6 female, mean age 58 years, 
mean length of Barrett’s oesophagus 4 cm) were treated with APC or PDT. Intestinal 
metaplasia without dysplasia was present in 16 patients, low-grade dysplasia in five, and 
high-grade dysplasia in eight patients. Biopsy samples were obtained at regular intervals 
(mean follow-up 20 months, range 6–36 months). One month after the first ablation, Barrett’s 
oesophagus was no longer identified, either endoscopically or 
histological, in nine patients (32%). At this time point, significant downgrading was 
achieved for abnormal chromosome 1 numbers (p = 0.020) and Ki67-defined proliferation 
(p = 0.002). Patients with residual Barrett’s oesophagus were additionally treated with APC, 
resulting in the elimination of Barrett’s oesophagus in 76% of all patients. However, at the 
last follow-up endoscopy, metaplasia without dysplasia was still present in five patients, and 
low- and high-grade dysplasia were each present in one patient. An abnormal chromosome 
1 number and p53 protein over expression were detected only in the high-grade dysplastic 
lesion, but increased proliferation was still present in the majority of these persisting cases. 
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This study shows that although endoscopic removal of Barrett’s oesophagus by ablative 
therapies is possible in the majority of patients, histological complete elimination cannot be 
achieved in all cases. More importantly, persistent Barrett’s oesophagus may still harbour 
molecular aberrations and must therefore be considered still to be at risk of progression to 
adenocarcinoma. 
 
Since the effect of ablative therapy at the genetic level is unclear, we studied the effect of 
APC and PDT on this level in further detail (CHAPTER 5). We performed loss of 
heterozygosity (LOH) analysis of BE in base line and follow-up biopsy specimens from 21 
patients with BE (17 male/ 4 female) treated with PDT and/or APC. At base line 14 patients 
had intestinal metaplasia without dysplasia (MET), 4 low-grade dysplasia (LGD) and 3 high-
grade dysplasia (HGD). LOH was assessed using a panel of 9 polymorphic markers for 
evaluation of the P53 gene on 17p, P16 on 9p, DCC and SMAD4 on 18q and the APC gene 
on 5q. The tissue specimens obtained at base line (t=0) were analysed, as well as the first 
(t=1; mean interval: 4 months) and last (t=2; mean interval: 8 months) available biopsy with 
residual or recurrent BE after ablation. At t=0 allelic loss was detected of 5q in 27%, 9p in 
56%, 17p in 31% and 18q in 6% of informative cases. At t=1 (18 patients with persistent 
MET and 3 with LGD) and at t=2 (8 MET, 2 LGD) the LOH patterns were not statistically 
different from t=0. Further, multiple genetic lineages before and after therapy were detected 
in 15 cases illustrating the multiclonal nature of BE. We concluded that recurrent and/or 
persistent BE after ablative therapy still contains genetic alterations associated with malignant 
progression to cancer. Therefore, the goal of treatment should be the complete elimination of 
Barrett’s mucosa.  
 
In conclusion, Barrett’s oesophagus is a premalignant condition and a risk factor for 
developing adenocarcinoma. The precise risk is not easy to establish, however may be lower 
than previously suggested. Moreover, most of the patients who develop adenocarcinoma do 
not die as a result of this cancer. Screenings programmes which aim at detecting early stage 
disease, with the idea that survival might be prolonged, therefore might not be that necessary.  
Unfortunately, this thesis also shows that ablative therapies, like APC and PDT, seldom result 
in complete elimination of BO. Moreover, in persisting and /or recurrent BO still cell 
biological and genetic alterations can be found associated with malignant progression. 
Therefore, these techniques cannot be used for prophylaxis. At present, patients treated with 
ablation therapy will therefore still need (rigorous biopsy) surveillance.  
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Barrett-slokdarm (BO) is een aandoening waarbij het bekledend plaveiselcelepitheel van de 
slokdarm is veranderd (metaplasie) in een slijmvliesepitheel dat meer lijkt op het bekledend 
epitheel van de darm en daarom wordt dit proces intestinale metaplasie genoemd. 
Er is gebleken dat patiënten met Barrett-slokdarm een verhoogd risico op het ontwikkelen van 
slokdarmkanker hebben. In vergelijking met de algemene bevolking blijkt dit risico 30-40 
maal verhoogd te zijn. Gedurende de afgelopen decennia is de incidentie van slokdarmkanker 
alarmerend toegenomen. De belangrijkste risicogroep bestaat uit blanke mannen uit een hoger 
socio-economisch milieu. Echter, de in de verleden gepubliceerde data over de incidentie van 
slokdarmkanker bij patiënten met een zgn. Barrett-slokdarm zijn moeilijk interpreteerbaar, 
aangezien in het verleden de diagnose werd gesteld op basis van de bevindingen van 
afwijkend slijmvlies bij endoscopisch onderzoek. Dit afwijkende slijmvlies moest bovendien 
over een lengte van tenminste 3 cm aanwezig zijn. Tegenwoordig vereist de diagnose Barrett-
slokdarm, naast een afwijkend aspect van het slokdarmslijmvlies, de aanwezigheid van 
intestinale metaplasie in endoscopisch verkregen weefselstukjes (biopten) bij weefsel, c.q. 
histologisch onderzoek. Bovendien is er heden een ontwikkeling gaande dat ook patiënten 
met een zeer kort segment (< 3 cm) met afwijkend slokdarmslijmvlies en/of het vinden van 
afwijkend epitheel in biopten zonder dat er sprake is van waarneembaar afwijkend slijmvlies, 
de diagnose Barrett-slokdarm krijgen. 
In het onderzoek dat beschreven wordt in HOOFDSTUK 2 hebben we de biopten van een 
groep patiënten met Barrett-slokdarm (≥ 3 cm), waarbij de diagnose reeds tussen 1973 en 
1984 was gesteld (het Rotterdams Barrett-cohort) opnieuw bekeken en de patiënten met zowel 
endoscopisch als histologisch afwijkend slijmvlies in de studie geincludeerd. Deze patiënten 
kregen bovendien in het verleden geen regelmatig endoscopisch onderzoek om het eventueel 
ontwikkelen van kanker eerder op te sporen, zoals tegenwoordig geadviseerd is.  
In totaal waren dit 105 patiënten. Met behulp van vragenlijsten en telefonische gesprekken, 
naar en met behandelend (huis)artsen of de patiënten zelf, werd deze groep benaderd om zo te 
achterhalen wie van hen uiteindelijk slokdarmkanker had gekregen of bekend waren met een 
voorstadium van slokdarmkanker [(te weten hooggradige dysplasie (HGD)] en/of ze 
eventueel aan deze aandoening waren overleden. Hiernaast werd gekeken of er factoren, die 
een risicofactor voor het ontwikkelen van slokdarmkanker kunnen zijn, bij deze patiënten 
aanwezig waren vanaf het moment dat de diagnose endoscopisch was gesteld. Deze factoren 
betroffen onder andere meer onschuldige voorstadia van slokdarmkanker [(te weten 
laaggradige dysplasie (LGD)], de aanwezigheid van zweren in het afwijkende slijmvlies en de 
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lengte van het afwijkende slijmvlies). Met behulp van een Kaplan-Meier analyse werd het 20-
jaars risico op het ontwikkelen van adenocarcinoom bepaald.  
De gemiddelde lengte van het afwijkende slijmvlies was 7.1 cm (spreiding 3-15 cm). 
Slokdarmkanker werd in 6/105 (6%) patiënten vastgesteld, HGD in 5/105 (5%) patiënten 
tijdens een tijdperiode van in totaal 1329 jaar (patiëntjaren). Het voorkomen van 
slokdarmkanker in deze groep was derhalve 1 op 221 patiëntjaren en het voorkomen van 
HGD 1 op 266 patiëntjaren. De duur dat deze groep gemiddeld werd gevolg bedroeg 12,7 
jaar. In deze tijdsperiode waren 72 patiënten overleden (69%); echter maar 4 patiënten waren 
tengevolge van, of aan de behandeling voor, slokdarmkanker overleden. Een grotere lengte 
van het Barrett-slijmvlies bleek een risicofactor (p=0.02) en 6 van  in totaal 24 patiënten die 
ooit (zowel op het tijdstip dat de diagnose BO werd gesteld, alsmede tijdens 
vervolgonderzoek dat meestal als gevolg van klachten werd verricht) LGD hadden, bleken 
later HGD of slokdarmkanker te hebben gekregen. Dit 2-16 jaar na het stellen van de 
diagnose BO. 
De conclusies van dit onderzoek waren dat het risico voor patiënten met BO om HGD of 
slokdarmkanker te ontwikkelen laag is, ondanks dat de gemiddelde lengte van het afwijkende 
slijmvlies erg lang was, namelijk 0.83% per jaar. Ook blijken patiënten die slokdarmkanker 
hebben gekregen hier niet vaak aan te overlijden. 
 
  
Omdat het bekend is dat Barrett-slokdarm een verhoogd risico op slakdarmkanker geeft, 
worden patiënten met deze aandoening regelmatig door de gastro-enteroloog gezien in zgn. 
surveillanceprogramma’s met als doel vroegstadia van kwaadaardige ontaarding (LGD en 
HGD) te ontdekken zodat een ingrijpende operatie, waarbij het aangedane deel van de 
slokdarm wordt verwijderd met een hoog risico op morbiditeit en mortaliteit, die aanbevolen 
wordt wanneer HGD wordt vastgesteld, voorkomen kan worden. Screening is tijdrovend en 
kostbaar. Tegenwoordig zijn technieken, met als doel het afwijkende slijmvlies te verwijderen 
(ablatie), die tijdens een standaard endoscopisch onderzoek gebruikt kunnen worden, daarom 
erg populair. Op deze manier kan de kans op kwaadaardige ontaarding deels of compleet 
weggenomen worden en zo mogelijk ook de noodzaak tot screening wegnemen.  
De meest gebruikte technieken zijn thermale destructie door argon plasma coagulatie (APC) 
en fotochemische destructie met fotodynamische therapie, dat gebaseerd is stapeling van de 
lichtgevoelige stof protoporfyrine IX (PpIX) in weefsels. PpIX kan in pure vorm intraveneus 
toegediend worden, maar ook de stof 5-aminolevulinezuur (ALA), een voorloper van de 
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haemsynthese, zorgt na toediening voor een endogene stapeling van PpIX. Bovendien kan 
ALA via de mond ingenomen worden. PpIX wordt door middel van licht geactiveerd. Dit 
resulteert in de productie van zuurstofradicalen die het weefsel beschadigen. 
Met deze technieken kan zowel Barrett zonder dysplastische veranderingen (intestinale 
metaplasie) als met dysplastische veranderingen (LGD en HGD) verwijderd worden met 
slagingspercentages van tot wel 98% (HOOFDSTUK 1). 
 
In de studie, beschreven in HOOFDSTUK 3, hebben we gekeken welke van de bovenstaande 
technieken het meest effectief was om Barrett-slijmvlies te verwijderen.  
Patiënten met BO (n=32 zonder dysplasie en n=8 met laaggradige dysplasie) werden 
gerandomiseerd is 1 van in totaal drie behandelingsvormen: (a) ALA gevolg na 4 uur door 
een enkele PDT 100J/ cm2 (PDT100; n=13),  (b) ALA gevolgd na 1 uur en 4 uur door 
respectievelijk PDT 20J/cm2 en 100J/cm2 (PDT20+100; n=13) en (c) APC met een 
“powersetting”van 65W in 2 sessies met een maand tussenpauze (APC; n=14). Als ablatie na 
1 maand niet volledig was verwijderd met deze behandelingsvormen, werden maximaal 2 
aanvullende behandelingen met APC gegeven. 
De gemiddelde afname van BO bedroeg 6 weken na behandeling 51% (spreiding 20-100%) in 
de PDT-groep, 86% (spreiding 0-100%) in de PDT20+100-groep en 93% (spreiding 40-100% 
in de APC-groep (PDT100 versus PDT20+100, p<0.005; PDT100 versus APC, p,0.005, NS) 
met histologisch complete verwijdering in 1/13 (8%) patiënten in de PDT-groep, 4/12 (33%) 
in de PDT20+100-groep en 5/14 (36%) patiënten in de APC-groep. Resterend Barrett-
slijmvlies werd in 23/40 (58%) van de patiënten met aanvullende APC behandelingen 
verwijderd.  
Bij histologisch onderzoek 12 maanden na behandeling bleek complete ablatie bereikt in 9/11 
(82%) patiënten in de PDT100-groep, in 9/10 (90%) in de PDT20+100-groep en in 8/12 
(67%) in de APC-groep (NS). Dysplasie werd in geen van de afgenomen biopten 
aangetroffen. Bijwerkingen, (te weten pijn (p<0.01), misselijkheid en braken (p<0.05) en 
verhoogde leverenzymwaarden (c.q. transaminasen; p<0.01) werden vaker gezien na PDT dan 
APC. Een patiënt overleed 3 dagen na behandeling met PDT, vermoedelijk ten gevolge van 
een hartritmestoornis. 
De voornaamste conclusies die we na dit onderzoek konden stellen waren dat APC of ALA-
PDT, in combinatie met aanvullende behandelingen met APC, leidt tot complete ablatie van 
Barrett-slijmvlies in tenminste 2/3 deel van de patiënten als deze behandelingen worden 
gegeven in meerdere opeenvolgende sessies. Aangezien het doel van de behandeling een 
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complete verwijdering van het Barrettslijmvlies moet zijn, bevelen we deze technieken niet 
aan als profylactische behandelingsvormen. 
 
In een vervolgstudie werd het effect van ablatieve behandelingsvormen op celbiologisch en 
genetisch niveau onderzocht (HOOFDSTUK 4). De potentie tot kwaadaardige ontaarding 
werd bekeken met behulp van immunohistochemische technieken (IHC) en de DNA in situ 
hybridisatietechniek (ISH). Immunohistochemisch werd gekeken naar overmatige 
aanwezigheid (overexpressie) van het p53 eiwit en naar de mate van overexpressie 
aanwezigheid van de merker Ki-67 als maat voor de delingsactiviteit. Met behulp van ISH 
werd gekeken naar de ploidie status, oftewel of er een abnormaal chromosoom 1 aantal in de 
celkernen gevonden kon worden. 
Negenentwintig patiënten met BO (23 mannen en 6 vrouwen, gemiddelde leeftijd 58 jaar 
gemiddelde lengte van BO  4cm) werden behandeld met APC of PDT. Intestinale metaplasie 
zonder dysplasie was aanwezig in 16 patiënten, laaggradige dysplasie in vijf en hooggradige 
dysplasie in 8 patiënten. Biopten werden op regelmatige tijdstippen na behandeling 
afgenomen (gemiddelde volgduur 12 maanden, spreiding 6-36 maanden). Een maand na de 
eerste behandeling werd geen BO meer aangetroffen, zowel endoscopisch als histologisch) in 
9 patiënten (32%). Op dit tijdstip werd een statistisch significante afname gezien van een 
abnormaal chromosoom 1 aantal (p=0.020) en overexpressie van Ki-67 (p=0.002). Patiënten 
met resterend BO werden aanvullend behandeld met APC. Dit resulteerde in complete ablatie 
van BO in 76% van de patiënten. Echter, bij het laatste endoscopisch onderzoek werd bij 5 
patiënten nog steeds intestinale metaplasie zonder dysplasie gevonden, in twee andere 
patiënten werd zelfs resp. laaggradige-, en hooggradige dysplasie gevonden. 
Een abnormaal chromosoom 1 aantal werd uitsluitend nog in de biopten van de patiënt met 
hooggradige dysplasie gezien, echter een verhoogde delingsactiviteit werd in de overgrote 
meerderheid van de patiënten met resterend BO gevonden. 
Met deze studie werd aangetoond dat het mogelijk is om Barrett-slijmvlies te verwijderen, 
echter dat een histologisch complete ablatie niet in alle gevallen bereikt kan worden. Nog 
belangrijker, in achtergebleven Barrett-slijmvlies kunnen nog steeds afwijkingen op 
celbiologisch en genetisch niveau gevonden. Derhalve blijft er een risico op kwaadaardige 
ontaarding naar een adenocarcinoom bestaan. 
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 Om het effect van ablatieve behandelingsvormen op genetisch niveau nader te bestuderen 
werd het onderzoek uitgebreid met een studie naar verlies van heterozygotie (LOH, loss of 
heterozygosity). Dit onderzoek wordt beschreven in HOOFDTSTUK 5.  
De biopten van 21 patiënten (17 mannen en 4 vrouwen), zowel voor als na ablatie met PDT 
en/of APC, werden geanalyseerd met LOH. Bij aanvang van de studie hadden 14 patiënten 
intestinale metaplasie zonder dysplasie (MET), 4 laaggradige dysplasie (LGD) en 3 
hooggradige dysplasie (HGD). Er werden 9 polymorfe merkers gebruikt om het P53 gen 
gelegen op chromosoom 17p, P16 op 9p, DCC en SMAD4 op 18q en APC gen op 5q te 
evalueren. De biopten voor aanvang van de behandeling (t=0), de eerste biopten na 
behandeling (t=1; gemiddeld interval van afname 4 maanden) en de als laatst afgenomen 
biopten (t=2; gemiddeld interval van afname 8 maanden) met resterend of opnieuw 
teruggekeerd BO werden geanalyseerd indien nog materiaal over was. 
Op t=0 werd allelverlies gevonden in 27% van de informatieve patiënten op 5q, in 31% op 9p, 
in 31% op 17p en in 6% op 18q.  Op t=1 (18 patiënten met persisterend MET en 3 met LGD) 
en t=2 (8 MET, 2 LGD), werden geen statistisch significante verschillen in LOH-patronen 
gevonden ten opzichte van de LOH-patronen die op t=0 werden gevonden. Als opvallende 
bevinding werden bij 15 patiënten meerdere genetische profielen gezien, als strikt gekeken 
werd naar het voor en na behandeling afgenomen weefsel. Deze bevinding laat zien dat BO 
een multiclonaal ziekteproces is, i.e. binnen een segment BO kunnen verschillende genetische 
afwijkingen ontstaan. 
Opnieuw bleek met dit onderzoek dat afwijkingen op genetisch niveau, geassocieerd met 
kwaadaardige ontaarding, in persisterend  en/of teruggekeerd BO na behandeling, gevonden 
konden worden. 
 
Concluderend kan gesteld worden dat Barrett-slokdarm een premaligne aandoening is en een 
risico geeft op kwaadaardige ontaarding naar adenocarcinoom. Het risico is niet goed aan te 
geven, maar is misschien minder groot dan aanvankelijk werd gedacht. Bovendien blijkt dat 
als slokdarmkanker is ontstaan het merendeel hier niet aan te overlijden. Hierdoor zijn de 
huidige toegepaste, kostbare en tijdrovende, surveillanceprogramma’s, die tot doel hebben 
vroegstadia van maligne ontaarding te vinden (waarbij aangenomen wordt dat de 
overlevingskansen sterk verbeteren) misschien niet zo erg noodzakelijk. 
 Helaas blijkt ook uit dit proefschrift dat, ondanks intensieve behandeling met PDT en APC, 
in een aantal patiënten Barrett-slijmvlies (endoscopisch en/of histologisch) nog gevonden kan 
worden met in deze resten bovendien afwijkingen op celbiologisch en genetisch niveau, die 
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geassocieerd zijn met kwaadaardige ontaarding. Deze patiënten zullen daarom nog steeds 
endoscopisch gevolgd moeten worden, waarbij tevens veel biopten voor histologisch 
onderzoek zullen moeten worden afgenomen. Surveillanceprogramma’s zullen daarom 
voorlopig nog geen verleden tijd zijn. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 8 
132 
 
133 
DANKWOORD 
 
Ik bedankt allereerst Dr. Metselaar van de MDL. Herold, zonder jou had ik deze baan nooit 
gekregen vertelde je me! Lange tijd deelde je een kamer met mijn copromotor Peter Siersema. 
Toen, op het huwelijk van jouw zus met mijn oom, het onderzoek dat tot dit proefschrift heeft 
geleid, ter sprake kwam heb je waarschijnlijk een goed woordje voor me gedaan. Veel dank! 
 
Ik bedank mijn beide promotoren voor het vertrouwen dat ze in me gesteld hebben. 
Prof.dr. J.W. Oosterhuis (Wolter). U ken ik voornamelijk als mijn opleider. Ik bewonder uw 
gedrevenheid in het verrichten van onderzoek. Verder heb ik respect dat u ondanks uw drukke 
werkzaamheden vrijwel nooit verzuimt om aanwezig te zijn bij de wekelijkse 
maandagmiddag werkbesprekingen in het JNI om te luisteren waar de vele onderzoekers in 
ons instituut aan werken. Wij assistenten zouden ook regelmatig hierbij aanwezig moeten zijn 
om zo meer over de toepasbaarheid van diverse moleculaire technieken te weten te komen. 
Nu ik weer terug op de afdeling ben ga ik persoonlijk mijn mede-assistenten de noodzaak 
hiertoe bijbrengen. Dus collega assistenten: plan het maar vast in je agenda!. 
 
Prof.dr. E.J. Kuipers (Ernst). Ik ken u als een vriendelijke man, die oprecht interesse heeft 
voor de mensen met wie u samenwerkt. Elke gelegenheid dat ik u sprak kwamen we als snel 
op het onderwerp Pathologie. Na nu 3 jaar opleiding kan ik nog steeds zeggen. Ja, het is een 
mooi vak! 
 
Nu is de tijd om de personen die de grootste bijdrage aan dit onderzoek hebben geleverd te 
bedanken. Mijn beide copromotoren Dr. H. van Dekken (Herman) en Dr. P.D. Siersema 
(Peter). 
Herman, naast mijn copromotor ben je ook even mijn mentor geweest in de eerste fase van 
mijn opleiding tot Patholoog. Ondanks dat dit niet zo werkte als beoogt, ben je voor het 
superviseren van onderzoek in de wieg gelegd. Je hebt me op het been gehouden en zorgde 
vooral dat er tempo in het schrijven van artikelen bleef. Je hebt zoveel in de tijd gedaan dat dit 
dankwoord tekortschiet om het allemaal bij naam te noemen. Ik dank je met heel mijn hart! 
 
Peter, in de beginfase van dit onderzoek was jij de drijvende kracht. Je hield me, niet altijd 
naar mijn zin, vrij kort. Ik had dit alles niet zonder jou kunnen doen. De gigantische 
hoeveelheid tijd die jij in onderzoek en het begeleiden van onderzoekers steekt zal ik nooit in 
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mijn leven evenaren. Via jou raakte ik ook nog enigszins betrokken bij de afdeling MDL (en 
voornamelijk de onderzoekers van het MDL-lab). 
Zeker in het begin van mijn onderzoeksperiode voelde ik me wat eenzaam op de afdeling 
Pathologie. Ik viel een beetje tussen wal en schip. Ik hoorde niet echt bij de afdeling MDL, 
ondanks dat ik hier als artsonderzoeker aangesteld was, en ook niet echt bij de afdeling 
Pathologie. 
Mijn collega’s van het ISH-lab (Kees Vissers, Ronald van Marion, Mark van Duin, 
Josiane Wink-Godschalk, en in de beginfase van mijn onderzoek Janneke Alers, Pieter-Jaap 
Kruijtenburg, Peter “Brutus” Riegman) ben ik dan ook dankbaar dat ze de leegte hebben 
opgevuld! Het was erg gezellig. Ronald, toen jij kwam met stereo en supergoede muziek werd 
het nog veel gezelliger. Het labtaaltje bevreemdde me in het begin ’Wat zijn in hemelsnaam 
kabouterdildo’s? En wat bedoelen ze met “mannetjes en vrouwtjes” als ze in de vriezer 
graaien? Jullie hebben me allemaal wegwijs in het lab gemaakt. In het bijzonder dank ik Kees. 
Je hebt me vrijwel alle labvaardigheden bijgebracht, zoals een goede docent betaamt. Ik hoop 
dat je het nog lang volhoud nu je labwerk en doceren met elkaar afwisselt. Zonder jou had dit 
onderzoek niet kunnen slagen! Als we niet er al snel achter waren dat we het verkregen 
materiaal niet op de gebruikelijke wijze moesten verwerken, maar het zelf in de hand moesten 
houden, was er nooit voldoende materiaal over geweest om de immuno’s, in situ’s etc. op de 
verrichtten. Bovendien heb je de laatste losse eindjes voor me weggewerkt. Bedankt! 
 
Ook dank ik alle mensen van het Histologie-lab en het immunohistochemie-lab voor de 
gezellige koffiepauzes. Theo Henriquez bedankt voor de lekkere koekjes. Ik hoop dat de 
pennywafels nog niet verbannen zijn! 
 
Dr.Winand Dinjens bedank ik voor het medebeoordelen en het me leren interpreteren van de 
LOH-films. Ook bedank ik de mensen die voor hem werken en met name Hein Sleddens, die 
Kees en mij de fijne kneepjes van het PCR-en heeft bijgebracht. Bij deze moet ik Linetta 
Koppert ook niet vergeten. Je had goede tips en je altijd positieve instelling heeft me goed 
gedaan! 
 
Frank van der Panne bedank ik voor de spectaculaire foto’s! 
 
Ook mijn mede-assistenten van de Pathologie bedank ik (Karen, Elf, Natascha, Senada, 
Claudia, Maarten, Hilde, Rob, Vidjia, Julliette, Francien, Germaine en Renske). Jullie 
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allemaal gaven me positieve energie om door te gaan. Renske en Senada jullie zijn de 
volgende! 
 
Mijn paranimfen (Frouke van Ettekoven en Tjarda Wilbrink) bedank ik dat ze me willen 
ondersteunen in de beproeving. Ik waardeer het zeer dat jullie de zware kost, ondanks dat het 
niet in jullie straatje ligt, hebben voorbereid. 
 
Rest mij nog mijn familie te bedanken. Pa, je hebt een zware tijd gehad dit jaar. Fijn dat alles 
goed gaat met je! Ma, het zonnetje is weer in je leven gekomen. Ik geniet met je mee. Probeer 
het te behouden! Mijn broer Patrick en mijn zussen Agnes, Laura en Rilana, we gaan elkaar 
vanaf u vaker zien! Ik wens jullie alle goeds toe! 
 
En last but not least mij lieve schat Jeffrey. Je hebt heel wat te verduren gehad met mij. Ik 
was door de drukke werkzaamheden niet altijd even vrolijk. Je moet wel onvoorwaardelijk 
van me houden. Laten we nu gaan genieten en samen de volgende stap in het leven zetten! 
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CURRICULUM VITAE 
 
De auteur van dit proefschrift werd op 25 juli 1974 geboren in Lochem. Haar voorbereidend 
wetenschappelijk onderwijs doorliep zij vanaf 1986 op de RSG Lochem, tegenwoordig het 
Staring College, alwaar zij in 1992 haar diploma behaalde. In 1993 begon ze aan de studie 
Geneeskunde te Leiden. De artsenbul werd behaald in 2000. Tijdens haar studie heeft zij kort 
als onderzoeks-assistent gewerkt op het Center for Human Drug Research (CHDR) te Leiden. 
Haar keuzevak tijdens de co-schappen werd gevolgd op het Nederlands Forensisch Instituut 
(NFI) te Rijswijk alwaar ze gedurende drie maanden meeliep op de afdeling Pathologie o.l.v. 
Dr. R. Visser. Op de afdeling Pathologie te Leiden werd gedurende drie maanden een 
afstudeeronderzoek verricht naar het voorkomen van (viraal geïnduceerde) afwijkingen in 
baarmoederhalsuitstrijkjes bij een groep Surinaamse vrouwen o.l.v. C.W.F. Vermeulen. 
Na haar afstuderen is in oktober 2000 gestart met het onderzoek dat heeft geleid tot dit 
proefschrift op de afdeling Maag-, Darm-, en Leverziekten (hoofd: Prof. Dr. E.J. Kuipers) in 
een samenwerkingsverband met de afdeling Pathologie van het Erasmus MC te Rotterdam 
(begeleiders: Dr. P.D. Siersema en Dr. H. van Dekken). In oktober 2002 is zij gestart met de 
opleiding tot patholoog in het Erasmus MC te Rotterdam (opleiders Prof. Dr. J.W. Oosterhuis 
en Dr. M. den Bakker). 
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LIST OF ABBREVIATIONS 
 
 
BO  Barrett´s oesophagus 
MET  Intestinal metaplasia 
LGD  Low-grade dysplasia 
HGD  High-grade dysplasia 
APC  Argon plasma coagulation 
PDT  Photodynamic therapy 
ALA  5-aminolevulinic acid 
PpIX  Protoporphyrin IX 
IHC  Immunohistochemistry 
ISH  In situ hybridisation 
LOH  Loss of heterozygosity 
PCR  Polymerase chain reaction 
P53  protein of 53 kilodalton 
DO-7  monoclonal antibody against p53 
Mib-1  monoclonal antibody against Ki-67 antigen 
17p  Short arm of chromosome 17 
9p  Short arm of chromosome 9 
5q  Long arm of chromosome 5 
18q  Long arm of chromosome 18 
PBS  Phosphate buffered saline 
DAB  Diaminobenzidine tetrachloride 
J  Joule 
W  Watt 
 
 
 
 
